<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:07:03Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9022442" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9022442</identifier>
        <datestamp>2022-04-21</datestamp>
        <setSpec>nihpa</setSpec>
        <setSpec>pmc-open</setSpec>
        <setSpec>manuscript</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-journal-id">8802730</journal-id>
              <journal-id journal-id-type="pubmed-jr-id">6431</journal-id>
              <journal-id journal-id-type="nlm-ta">Prostaglandins Leukot Essent Fatty Acids</journal-id>
              <journal-id journal-id-type="iso-abbrev">Prostaglandins Leukot Essent Fatty Acids</journal-id>
              <journal-title-group>
                <journal-title>Prostaglandins, leukotrienes, and essential fatty acids</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0952-3278</issn>
              <issn pub-type="epub">1532-2823</issn>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9022442</article-id>
              <article-id pub-id-type="pmcid">PMC9022442</article-id>
              <article-id pub-id-type="pmc-uid">9022442</article-id>
              <article-id pub-id-type="pmid">34077887</article-id>
              <article-id pub-id-type="pmid">34077887</article-id>
              <article-id pub-id-type="doi">10.1016/j.plefa.2021.102302</article-id>
              <article-id pub-id-type="manuscript">nihpa1773009</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Secondary data analysis investigating effects of marine omega-3 fatty acids on circulating levels of leptin and adiponectin in older adults</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rausch</surname>
                    <given-names>J.A.</given-names>
                  </name>
                  <degrees>Ph.D., RN</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                  <xref rid="CR1" ref-type="corresp">*</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gillespie</surname>
                    <given-names>S.</given-names>
                  </name>
                  <degrees>Ph.D., RN</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Orchard</surname>
                    <given-names>T.</given-names>
                  </name>
                  <degrees>Ph.D., MS, RD</degrees>
                  <xref rid="A2" ref-type="aff">b</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tan</surname>
                    <given-names>A.</given-names>
                  </name>
                  <degrees>Ph.D., MD</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McDaniel</surname>
                    <given-names>J.C.</given-names>
                  </name>
                  <degrees>Ph.D., RN</degrees>
                  <xref rid="A1" ref-type="aff">a</xref>
                </contrib>
              </contrib-group>
              <aff id="A1"><label>a</label>The Ohio State University, College of Nursing, 1585 Neil Avenue, Columbus, Ohio 43210</aff>
              <aff id="A2"><label>b</label>The Ohio State University, College of Education and Human Ecology, 1585 Neil Avenue, Columbus, Ohio 43210</aff>
              <author-notes>
                <fn fn-type="other" id="FN1">
                  <p id="P1">Author statement</p>
                  <p id="P2">The authors, Jamie Rausch, Ph.D., RN; Shannon Gillespie, Ph.D., RN; Tonya Orchard, Ph.D., MS, RD; Alai Tan, Ph.D., MD; and Jodi C. McDaniel, Ph.D., RN, certify that the final submitted version of this manuscript, all figures, and tables are our original work, have not been previously published, and are not under consideration for publication elsewhere. All authors have seen and approve the final version of the manuscript submitted on May 13, 2021.</p>
                  <p id="P3">The authors declare that similarly to the original submitted manuscript there remain no conflict of interest for any of the authors.</p>
                  <p id="P4">All figures and tables in this manuscript are original and created by the authors, and, as such, permission to use them are not needed from outside sources.</p>
                  <p id="P5">Electronically signed May 13, 2021:</p>
                  <p id="P6">Jamie Rausch, Ph.D., RN</p>
                  <p id="P7">Shannon Gillespie, Ph.D., RN</p>
                  <p id="P8">Tonya Orchard, Ph.D., MS, RD</p>
                  <p id="P9">Alai Tan, Ph.D., MD</p>
                  <p id="P10">Jodi C. McDaniel, Ph.D., RN</p>
                </fn>
                <fn fn-type="con" id="FN11">
                  <p id="P11">Author contributions</p>
                  <p id="P12">JR contributed to the study design, analysis, and primary authorship of this manuscript. JM, as primary investigator of the parent study, assisted with current study design, analysis, and manuscript writing and reviewing. TO, AT, and SG gave substantial feedback during the study design phase and assisted in the analysis, and manuscript writing and reviewing.</p>
                </fn>
                <corresp id="CR1"><label>*</label>Correspondence Author. Jamie A. Rausch, Ph.D., RN, Indiana University Fort Wayne, School of Nursing, 2101 E Coliseum Blvd, Liberal Arts 309B, Fort Wayne, Indiana 46805, Phone number: 260-257-6811. <email>rauschj@iu.edu</email> (J.A. Rausch).</corresp>
              </author-notes>
              <pub-date pub-type="nihms-submitted">
                <day>26</day>
                <month>1</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>7</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>24</day>
                <month>5</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>21</day>
                <month>4</month>
                <year>2022</year>
              </pub-date>
              <volume>170</volume>
              <fpage>102302</fpage>
              <lpage>102302</lpage>
              <permissions>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
                </license>
              </permissions>
              <abstract id="ABS1">
                <sec id="S1">
                  <title>Background:</title>
                  <p id="P13">Higher leptin and lower adiponectin levels have been linked to progressing systemic inflammation and diseases of aging. Among older adults with obesity and an inflammatory conditions, we quantified effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on leptin, adiponectin, and the leptin-to-adiponectin ratio (LAR). We also examined associations among adipokine and cytokine levels.</p>
                </sec>
                <sec id="S2">
                  <title>Methods:</title>
                  <p id="P14">Using a randomized, double-blind, placebo-controlled design, participants (mean age 61.3 ± 2.1) received 1.5 g EPA + 1.0 g DHA (<italic toggle="yes">n</italic> = 14) or mineral oil (<italic toggle="yes">n</italic> = 18) daily. Plasma adipokine and cytokine levels were quantified by electrochemiluminescence at all study intervals.</p>
                </sec>
                <sec id="S3">
                  <title>Results:</title>
                  <p id="P15">While no between-group differences were detected, there was a reduction in the LAR (by 23%, <italic toggle="yes">p</italic>=.065) between weeks 4 and 8 among the EPA+DHA group. Adiponectin levels were negatively associated with IL-1β levels at week 4 (<italic toggle="yes">p</italic>=.02) and TNF-α levels at week 8 (<italic toggle="yes">p</italic>=.03).</p>
                </sec>
                <sec id="S4">
                  <title>Conclusion:</title>
                  <p id="P16">Potential benefits of EPA+DHA supplementation among aging populations warrant further study.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd>Leptin</kwd>
                <kwd>Adiponectin</kwd>
                <kwd>Leptin-to-adiponectin ratio</kwd>
                <kwd>Inflammation</kwd>
                <kwd>EPA</kwd>
                <kwd>DHA</kwd>
              </kwd-group>
            </article-meta>
          </front>
          <body>
            <sec id="S5">
              <label>1.</label>
              <title>Introduction</title>
              <p id="P17">Chronic systemic inflammation has been linked to diseases of aging that introduce significant risk for morbidity and mortality [e.g., cardiovascular disease (CVD), diabetes mellitus (DM), depression] [<xref rid="R1" ref-type="bibr">1</xref>–<xref rid="R5" ref-type="bibr">5</xref>]. So strong is the relationship between aging and systemic inflammation that it inspired the term inflammaging [<xref rid="R6" ref-type="bibr">6</xref>]. Studies have begun to uncover multiple metabolic and immune-related antecedents to inflammaging [<xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>], with findings of rising leptin and diminishing adiponectin levels increasingly implicated.</p>
              <p id="P18">Adipose tissue (AT) stores excess energy as fat and also functions as an endocrine organ, producing leptin and adiponectin to help regulate feeding behavior, energy expenditure, and inflammation [<xref rid="R8" ref-type="bibr">8</xref>]. After secretion by adipocytes, leptin and adiponectin enter the peripheral circulation and act as regulatory hormones that communicate with other organs including the brain, liver, and immune system [<xref rid="R7" ref-type="bibr">7</xref>–<xref rid="R9" ref-type="bibr">9</xref>]. Excess AT, as seen in obesity and aging, leads to an imbalance in circulating levels of leptin and adiponectin, which also has significant immune implications [<xref rid="R10" ref-type="bibr">10</xref>–<xref rid="R12" ref-type="bibr">12</xref>]. Leptin’s actions are primarily proinflammatory and the leptin receptor (<italic toggle="yes">LEPR</italic>) is ubiquitously distributed in nearly all immune cells [<xref rid="R10" ref-type="bibr">10</xref>–<xref rid="R14" ref-type="bibr">14</xref>]. Conversely, adiponectin has been shown to counteract pro-inflammatory mediators [<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R15" ref-type="bibr">15</xref>–<xref rid="R17" ref-type="bibr">17</xref>], and up-regulate expression of anti-inflammatory mediators [<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R17" ref-type="bibr">17</xref>] (<xref rid="F1" ref-type="fig">Fig. 1</xref>). Given the opposing actions of leptin and adiponectin, the leptin to adiponectin ratio (LAR) has shown particular promise as a biological reflection of increased disease risk [<xref rid="R18" ref-type="bibr">18</xref>–<xref rid="R22" ref-type="bibr">22</xref>].</p>
              <p id="P19">Some [<xref rid="R23" ref-type="bibr">23</xref>–<xref rid="R27" ref-type="bibr">27</xref>] but not all [<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R29" ref-type="bibr">29</xref>] randomized clinical trials (RCTs) report beneficial effects of omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) supplementation on leptin and adiponectin levels (<xref rid="F2" ref-type="fig">Fig. 2</xref>). EPA and DHA are long known for their anti-inflammatory effects [<xref rid="R25" ref-type="bibr">25</xref>–<xref rid="R33" ref-type="bibr">33</xref>]. They are also thought to positively affect leptin and adiponectin levels by promoting a healthy weight [<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>], reducing the size of adipocytes [<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>], improving insulin sensitivity [<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R35" ref-type="bibr">35</xref>], reducing the expression of genes that encode for leptin, and increasing the expression of genes that encode for adiponectin [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R30" ref-type="bibr">30</xref>] (<xref rid="T1" ref-type="table">Table 1</xref>). Discrepancies in trial findings may be related to differing doses or lengths of supplementation, with at least 2 g/d of EPA and DHA daily over at least 4 weeks appearing to be required to reap the expected benefit [<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>]. It also remains to be determined whether likelihood of benefit depends upon the demographics or clinical characteristics of the population under study.</p>
              <p id="P20">Using data from a randomized, double-blind, placebo-controlled trial that determined the effects of daily 1.5 g EPA + 1.0 g DHA supplementation on biomarkers of inflammation after 4 and 8 weeks of treatment among adults aged 50 years and older with obesity and a chronic inflammatory condition [<xref rid="R33" ref-type="bibr">33</xref>], we assessed the effects of the intervention on plasma levels of leptin, adiponectin, and the LAR at the same time points. To further our understanding of the role of leptin and adiponectin in inflammaging in this population, we also examined associations among plasma leptin, adiponectin, the LAR, and pro-inflammatory cytokine levels. We hypothesized that EPA+DHA supplementation would be associated with lower leptin levels, higher adiponectin levels, and a lower LAR at 4 weeks and 8 weeks compared to placebo. We hypothesized that plasma leptin levels and the LAR would be positively associated, and plasma adiponectin levels would be negatively associated with plasma pro-inflammatory cytokine levels at both assessments.</p>
            </sec>
            <sec id="S6">
              <label>2.</label>
              <title>Participants and methods</title>
              <p id="P21">The current study is a secondary analysis of data generated by a RCT conducted between August 2012 and July 2015 in accordance with the Ethical Principles for Medical Research involving Human Subjects outlined in the Declaration of Helsinki in 1975 (last updated in 2018, see <ext-link xlink:href="https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medicalresearch-involving-human-subjects/" ext-link-type="uri">https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medicalresearch-involving-human-subjects/</ext-link>).</p>
              <sec id="S7">
                <label>2.1.</label>
                <title>Participant sample</title>
                <p id="P22">The study population consisted of patients recruited from two outpatient wound clinics affiliated with a large Midwestern medical center. Eligible participants were adults aged 50 to 85 years diagnosed with at least one chronic inflammatory condition (nonhealing venous leg ulcers). All participants completed the study protocol during three study visits (weeks 0, 4, and 8) at the medical center-affiliated clinical research center, after signing an informed consent document approved by the facility’s Institutional Review Board. Forty participants consented to the study with almost equal allocation to the two intervention groups (<italic toggle="yes">n</italic> = 21 for EPA+DHA Group and <italic toggle="yes">n</italic> = 19 for Control Group). After accounting for attrition, the final sample of the parent study included 35 people. There were complete data regarding plasma levels of leptin and adiponectin for 32 of the 35 participants in the parent study that were analyzed for the current study (EPA+DHA Group (<italic toggle="yes">n</italic> = 14), Control Group (<italic toggle="yes">n</italic> = 18). A general summary of patient flow through the parent study and inclusion in this secondary analysis is presented in the CONSORT diagram shown in <xref rid="F3" ref-type="fig">Fig. 3</xref>.</p>
              </sec>
              <sec id="S8">
                <label>2.2.</label>
                <title>Study design</title>
                <p id="P23">The parent study used a randomized, double-blind, placebo-controlled, repeated measures design to assess the effects of daily oral EPA+DHA supplementation versus placebo on levels of polyunsaturated fatty acid (PUFA)-derived inflammatory mediators, proinflammatory cytokines, and polymorphonuclear leukocytes in blood and wound fluid, and wound healing in older adults with chronic venous leg ulcers (CVLUs) (Trial registration: December 12, 2012 at <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> identifier <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT01754506" ext-link-type="uri">NCT01754506</ext-link>). The results of the analyses of primary outcome measures have been previously published [<xref rid="R26" ref-type="bibr">26</xref>]. For the current study, existing data from the parent study were analyzed to determine the effects of daily oral EPA+DHA supplementation versus placebo on plasma levels of leptin, adiponectin, and the LAR across the study interval (weeks 0, 4 and 8), and to evaluate associations between leptin, adiponectin, LAR, and the proinflammatory cytokines interleukin (IL)–6, IL-1β, and tumor necroses factor (TNF)-α.</p>
              </sec>
              <sec id="S9">
                <label>2.3.</label>
                <title>Study interventions</title>
                <p id="P24">All soft gels (EPA+DHA or mineral oil) were identical in appearance, lemon-flavored, and compounded and packaged in like containers by J. R. Carlson Laboratories, Inc. (Arlington Heights, IL) in order to eliminate detection of allocated group. The contents of the soft gels for the intervention group are listed in <xref rid="T2" ref-type="table">Table 2</xref>. Participants of both groups were instructed to store the soft gels in the refrigerator, take five soft gels and one tablet containing 81 mg of acetylsalicylic acid (ASA) daily with their evening meal (ASA was administered because it has been found to enhance specialized pro-resolving mediators (e.g., lipoxins, resolvins) from EPA and DHA [<xref rid="R48" ref-type="bibr">48</xref>]. Participants were also instructed to bring the bottles containing any remaining soft gels and tablets to the next study visit to determine adherence to the study protocol, refrain from using anti-inflammatory drugs, if possible, and maintain their usual diet with the exception of excluding fish, seafood, algae, kelp, and other nutritional supplements containing fish oil. Participants in the EPA+DHA group consumed a total dose of 2.5 g of EPA+DHA (1.5 g of EPA and 1.0 g of DHA), which has been previously shown to significantly increase plasma EPA+DHA levels [<xref rid="R34" ref-type="bibr">34</xref>] and decrease some inflammatory biomarkers after four weeks of supplementation [<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R36" ref-type="bibr">36</xref>]. A dose of up to 3.0 g/d is considered safe and acceptable for the general public [<xref rid="R37" ref-type="bibr">37</xref>]. Participants in the control group consumed a total daily dose of 2.5 mL of light mineral oil which included 0 g of EPA and 0 g of DHA. Mineral oil is chemically inert, with the majority (98%) remaining unabsorbed in the feces; a dose of 2.5 mL daily has not been associated with any adverse events in prior studies [<xref rid="R34" ref-type="bibr">34</xref>,<xref rid="R38" ref-type="bibr">38</xref>].</p>
              </sec>
              <sec id="S10">
                <label>2.4.</label>
                <title>Assessments</title>
                <p id="P25">Study visits were completed at week 0 (baseline), week 4, and week 8. At week 0, participants self-reported sociodemographic data via an electronic questionnaire and medication and comorbidity data via interviews by study nurses; all data were recorded using Research Electronic Data Capture (REDCap) [<xref rid="R39" ref-type="bibr">39</xref>]. Sociodemographic data included gender, age, race, marital status, employment status, income, highest level of education completed, and the total number of people in their household. Medical records were reviewed by study staff to confirm health history data. Fasting blood samples were collected at all three study time points. Levels of serum leptin and adiponectin were determined by electrochemiluminescence using Human Leptin and Adiponectin kits and the Meso QuickPlex SQ 120 (Meso Scale Discovery, Rockville, MD). Per the manufacturer, the specificity or lower limit of detection for leptin and adiponectin are 0.00578 and 0.0013 ng/ml, respectively [<xref rid="R40" ref-type="bibr">40</xref>,<xref rid="R41" ref-type="bibr">41</xref>]. Plasma PUFA levels were analyzed by the well-established gas chromatography method [<xref rid="R42" ref-type="bibr">42</xref>]. Levels of proinflammatory cytokines (IL-1β, IL-6, and TNF-α) were quantified using Invitrogen (1600 Faraday Avenue Carlsbad, CA, 92,008) Human ELISAs for IL-1β (cat# KHC0014), IL-6 (cat# KHC0061) and TNFα (cat# KHC3011) [<xref rid="R33" ref-type="bibr">33</xref>].</p>
              </sec>
              <sec id="S11">
                <label>2.5.</label>
                <title>Statistical methods</title>
                <p id="P26">Congruent with the RCT design of the parent study, we conducted an intent-to-treat analysis. We analyzed data from the participants for whom samples had been collected at all three time points for leptin and adiponectin plasma levels. We used descriptive statistics to summarize sample characteristics. Both histograms and Kolmogorov-Smirnov tests revealed that the leptin, adiponectin, and LAR data were not normally distributed. Therefore, we conducted transformation using a two-step process [<xref rid="R43" ref-type="bibr">43</xref>]. The first step requires transforming the variable into a percentile rank, resulting in a uniform distribution. In the second step, an inverse-normal transformation is applied to the results from the first step guided by the mean and standard error of the original variable to achieve normal distribution with the same mean and standard error. Two-sample T-tests and Chi-square statistics were used to check the balance of study groups in baseline measures. Paired <italic toggle="yes">t</italic>-tests were used to examine within-group change from baseline across the study time points for each intervention group. Independent sample <italic toggle="yes">t</italic>-tests were conducted to compare mean levels of leptin, adiponectin, and LARs between treatment groups at each time point. We also compared the change from baseline in levels of leptin, adiponectin, and LARs between treatment groups at week 4 and week 8 using two-sample <italic toggle="yes">t</italic>-tests. Pearson <italic toggle="yes">r</italic> correlations were conducted to assess the relationship between the following variables: leptin, adiponectin, and LAR to IL-6, IL-1β, and TNF-α. All tests were two-sided at a significance level of 0.05.</p>
                <p id="P27">Due to the pilot nature of the study, the small sample size may not provide sufficient power to detect statistical significance. Therefore, we calculated Cohen’s <italic toggle="yes">d</italic> for the between-group comparisons. The cutoffs of 0.2, 0.5, and 0.8 indicate small, medium, and large effect sizes, respectively. Statistical Package for the Social Sciences version 25.0 for Windows was used for all data analyses (SPSS, Chicago, IL).</p>
              </sec>
            </sec>
            <sec id="S12">
              <label>3.</label>
              <title>Results</title>
              <sec id="S13">
                <label>3.1.</label>
                <title>Participant characteristics</title>
                <p id="P28">The majority of participants included in this secondary analysis were older (age: <italic toggle="yes">M</italic>±SD = 61.3 ± 2.1), white (62.5%), males (62.5%), who were obese (BMI: <italic toggle="yes">M</italic>±SD = 41.5 ± 2.1) and had an average of two comorbidities in addition to a CVLU diagnosis. Our sample of 32 participants included patients diagnosed with multiple chronic inflammatory conditions in addition to CVLUs, such as CVD (<italic toggle="yes">n</italic> = 25), DM (<italic toggle="yes">n</italic> = 16), arthritis (<italic toggle="yes">n</italic> = 15), and depression (<italic toggle="yes">n</italic> = 8). At baseline, the two treatment groups were balanced based on the descriptive characteristics (<xref rid="T3" ref-type="table">Table 3</xref>).</p>
              </sec>
              <sec id="S14">
                <label>3.2.</label>
                <title>Effects of treatment</title>
                <sec id="S15">
                  <label>3.2.1.</label>
                  <title>Plasma levels of epa+dha</title>
                  <p id="P29">The mean plasma levels of EPA+DHA at the study time points for both groups are displayed in <xref rid="F4" ref-type="fig">Fig. 4</xref>. The EPA+DHA Group had significantly higher plasma levels of EPA+DHA at week 4 (<italic toggle="yes">M</italic> = 5.01, SE = 0.56) and at week 8 (<italic toggle="yes">M</italic> = 5.48, SE = 0.53) compared to week 0 (<italic toggle="yes">M</italic> = 2.02, SE = 0.18), t(13) = −5.12, <italic toggle="yes">p</italic> &lt; .001, t(13) = −7.44, <italic toggle="yes">p</italic> &lt; .001, respectively. Conversely, there were no significant differences in plasma levels of EPA+DHA across time in the Control Group (week 0: <italic toggle="yes">M</italic> = 1.95, SE = 0.11; Week 4: <italic toggle="yes">M</italic> = 1.92, SE = 0.13; week 8: <italic toggle="yes">M</italic> = 1.92, SE = 0.14), t(17) = 0.438, <italic toggle="yes">p</italic> = .67, t(17) = 0.437, <italic toggle="yes">p</italic> = .67, respectively. At week 0, the mean plasma levels of EPA+DHA between the EPA+DHA Group (<italic toggle="yes">M</italic> = 2.02, SE = 0.18) and Control Group (<italic toggle="yes">M</italic> = 1.95, SE = 0.11) were not significantly different, t(30) = 0.37, <italic toggle="yes">p</italic> = .71, <italic toggle="yes">d</italic> = 0.12. However, the between-group analyses showed that the plasma levels of EPA+DHA were significantly higher in the EPA+DHA Group at week 4 (<italic toggle="yes">M</italic> = 5.01, SE = 0.56) and at week 8 (<italic toggle="yes">M</italic> = 5.48, SE = 0.53) compared to the Control Group (week 4: <italic toggle="yes">M</italic> = 1.92, SE = 0.13; week 8: <italic toggle="yes">M</italic> = 1.92, SE = 0.14), t(30) = 5.997, <italic toggle="yes">p</italic> &lt; .001, <italic toggle="yes">d</italic> = 2.01; t(30) = 7.218, <italic toggle="yes">p</italic> &lt; .001, <italic toggle="yes">d</italic> = 2.42, respectively.</p>
                </sec>
                <sec id="S16">
                  <label>3.2.2.</label>
                  <title>Leptin, adiponectin, and LAR</title>
                  <p id="P30"><xref rid="T4" ref-type="table">Table 4</xref> shows the transformed leptin, adiponectin, and LAR data at weeks 0, 4, and 8, by treatment group.</p>
                  <p id="P31">The within-group analyses showed no significant differences in mean plasma levels of leptin over the study interval in the Control group or in the EPA+DHA group. The between-group analyses showed that the mean plasma levels of leptin of the EPA+DHA and Control groups were not significantly different (week 0: <italic toggle="yes">M</italic> = 56.21, SE=14.16 vs. <italic toggle="yes">M</italic> = 79.07, <italic toggle="yes">SE</italic> = 16.94; week 4: <italic toggle="yes">M</italic> = 72.62, <italic toggle="yes">SE</italic> = 10.76 vs. <italic toggle="yes">M</italic> =; week 8: <italic toggle="yes">M</italic> = 60.26, <italic toggle="yes">SE</italic> = 13.12 vs. <italic toggle="yes">M</italic> = 83.37, <italic toggle="yes">SE</italic> = 17.21). However, a small-to-medium effect size of the between-group difference was identified at week 0 (<italic toggle="yes">d</italic> = 0.37) and week 8 (<italic toggle="yes">d</italic> = 0.29).</p>
                  <p id="P32">Due to differences in mean leptin levels at baseline, the changes in mean levels of leptin were calculated and between-group analyses were conducted. Although small difference in means was identified, the mean change of leptin was not statistically significantly different between groups from week 0 to week 4, week 4 to week 8, or total change week 0 to week 8, <italic toggle="yes">t</italic>(29) = 0.89, <italic toggle="yes">p</italic> = .38, <italic toggle="yes">d</italic> = 0.32, <italic toggle="yes">t</italic>(29) = −0.66, <italic toggle="yes">p</italic> = .52, <italic toggle="yes">d</italic> = 0.23, <italic toggle="yes">t</italic>(29) = 0.60, <italic toggle="yes">p</italic> = .55, <italic toggle="yes">d</italic> = 0.23, respectively.</p>
                  <p id="P33">The within-group analyses of adiponectin levels showed no significant changes in the Control group when comparing week 0 (<italic toggle="yes">M</italic> = 27.15, SE = 6.76) to week 4 (<italic toggle="yes">M</italic> = 29.21, SE = 6.46), or week 0 to week 8 (<italic toggle="yes">M</italic> = 32.92, SE = 5.23), <italic toggle="yes">t</italic>(16) = −0.41, <italic toggle="yes">p</italic> = .69, <italic toggle="yes">t</italic>(16) = −1.17, <italic toggle="yes">p</italic> = .26, respectively. However, the mean plasma levels of adiponectin in the Control group were higher at week 8 (<italic toggle="yes">M</italic> = 32.92, SE = 5.23) compared to week 4 (<italic toggle="yes">M</italic> = 29.21, SE = 6.46), <italic toggle="yes">t</italic>(16) = 1.8, <italic toggle="yes">p</italic> = .09. The within-group analysis of the EPA+DHA group showed no significant changes in mean plasma levels of adiponectin over the study interval (week 0: <italic toggle="yes">M</italic> = 17.22, SE = 8.73; week 4: <italic toggle="yes">M</italic> = 16.48, SE = 8.61; week 8: <italic toggle="yes">M</italic> = 10.73, SE = 8.76).</p>
                  <p id="P34">The mean plasma levels of adiponectin in the EPA+DHA group vs. the Control group were not significantly different at week 0 (<italic toggle="yes">M</italic> = 17.22, SE = 8.73 vs. <italic toggle="yes">M</italic> = 27.15, SE = 6.76) or week 4 (<italic toggle="yes">M</italic> = 16.48, SE = 8.61 vs. <italic toggle="yes">M</italic> = 29.21, SE = 6.46). However, the between-group differences at week 0 and week 4 were of small-to-medium effect size (<italic toggle="yes">d</italic> = 0.33, and 0.43, respectively). At week 8, the mean plasma levels of adiponectin were significantly higher in the Control group (<italic toggle="yes">M</italic> = 32.92, SE = 5.23) compared to the EPA+DHA group (<italic toggle="yes">M</italic> = 10.73, SE = 8.76; <italic toggle="yes">p</italic> = .03) and a large effect size was identified (<italic toggle="yes">d</italic> = 0.80).</p>
                  <p id="P35">Due to differences in mean adiponectin levels at baseline, the changes in mean levels of adiponectin were calculated and between-group analyses were conducted. A small non-significant difference in change of mean adiponectin levels from week 0 to week 4 was identified between the EPA+DHA group (<italic toggle="yes">M</italic> = −0.7, SE = 5.8) and the Control group (<italic toggle="yes">M</italic> = 2.1, SE = 5.1), <italic toggle="yes">t</italic>(29) = −0.366, <italic toggle="yes">p</italic> = .72, <italic toggle="yes">d</italic> = 0.13. There was a medium non-significant difference in change of mean adiponectin levels from week 0 to week 8 between the EPA+DHA group (<italic toggle="yes">M</italic> = −6.5, SE = 5.5) and the Control group (<italic toggle="yes">M</italic> = 5.8, SE = 4.9), <italic toggle="yes">t</italic>(29) −1.66, <italic toggle="yes">p</italic> = .11, <italic toggle="yes">d</italic> = 0.60.</p>
                  <p id="P36">Concerning LARs, the within-group analyses of the Control group data detected no significant changes in mean plasma LARs over the study interval (week 0: <italic toggle="yes">M</italic> = 5.46, SE = 1.13; week 4: <italic toggle="yes">M</italic> = 5.88, SE = 1.62; week 8: <italic toggle="yes">M</italic> = 5.29, SE = 1.33). Likewise, there were no significant changes in the mean plasma LARs in the EPA+DHA group when comparing week 0 to week 4 or week 0 to week 8 (week 0: <italic toggle="yes">M</italic> = 6.64, SE = 1.53; week 4: <italic toggle="yes">M</italic> = 7.3, SE = 1.2; week 8: <italic toggle="yes">M</italic> = 5.6, SE = 1.5). However, the mean LAR was lower in the EPA+DHA group at week 8 compared to week 4, <italic toggle="yes">t</italic>(13) = −2.02, <italic toggle="yes">p</italic> = .065.</p>
                  <p id="P37">The between-group analyses showed that the mean plasma LARs for the EPA+DHA group (week 0: <italic toggle="yes">M</italic> = 6.64, SE = 1.53; week 4: <italic toggle="yes">M</italic> = 7.25, SE = 1.21; week 8: <italic toggle="yes">M</italic> = 5.64, SE = 1.45) compared to the Control group (week 0: <italic toggle="yes">M</italic> = 5.46, SE = 1.13; week 4: <italic toggle="yes">M</italic> = 5.88, SE = 1.62; week 8: <italic toggle="yes">M</italic> = 5.29, SE = 1.33) were not significantly different at any time point and the differences were of small effects sizes, <italic toggle="yes">t</italic>(29) = 0.63, <italic toggle="yes">p</italic> = .53, <italic toggle="yes">d</italic> = 0.23, <italic toggle="yes">t</italic>(29) = 0.66, <italic toggle="yes">p</italic> = .52, <italic toggle="yes">d</italic> = 0.24, <italic toggle="yes">t</italic>(29) = 0.18, <italic toggle="yes">p</italic> = .86, <italic toggle="yes">d</italic> = 0.08, respectively.</p>
                </sec>
              </sec>
              <sec id="S17">
                <label>3.3.</label>
                <title>Correlations</title>
                <p id="P38"><xref rid="T5" ref-type="table">Table 5</xref> displays the Pearson Correlation coefficients of relationships between leptin, adiponectin, LAR, and the proinflammatory cytokines IL-6, IL-1β, and TNF-α. In the EPA+DHA group, there was a significant negative correlation between mean plasma levels of adiponectin and mean plasma levels of IL-1β at week 4 and mean plasma levels of TNF-α at week 8, <italic toggle="yes">r</italic>(<italic toggle="yes">N</italic> = 14) = −0.63, <italic toggle="yes">p</italic> = .02, <italic toggle="yes">r</italic>(<italic toggle="yes">N</italic> = 14) = −0.60, <italic toggle="yes">p</italic> = .03, respectively. In the Control group, mean plasma levels of leptin showed a strong negative relationship to both mean plasma levels of adiponectin and TNF-α at week 8, <italic toggle="yes">r</italic>(<italic toggle="yes">N</italic> = 17) = −0.57, <italic toggle="yes">p</italic> = .02, <italic toggle="yes">r</italic>(<italic toggle="yes">N</italic> = 17) = −0.50, <italic toggle="yes">p</italic> = .04, respectively. Mean plasma levels of leptin were also shown to have a moderate negative relationship to mean plasma levels of adiponectin at week 4, <italic toggle="yes">r</italic>(<italic toggle="yes">N</italic> = 17) = −0.49, <italic toggle="yes">p</italic> = .05.</p>
              </sec>
            </sec>
            <sec id="S18">
              <label>4.</label>
              <title>Discussion and conclusions</title>
              <sec id="S19">
                <label>4.1.</label>
                <title>Relevance</title>
                <p id="P39">The daily dietary intake of the marine-derived omega-3 fatty acids EPA+DHA by the majority of people in the United States are below what many groups worldwide are currently recommending [<xref rid="R35" ref-type="bibr">35</xref>,<xref rid="R44" ref-type="bibr">44</xref>]. The World Health Organization advises adults (&gt;18 years of age) to consume 200–500 mg/d of EPA+DHA and the United States’ National Institute of Medicine recommends women in this same age group consume at least 110 mg/d of EPA+DHA and men to consume at least 160 mg/d of EPA+DHA [<xref rid="R45" ref-type="bibr">45</xref>]. Nonetheless, findings from two recent studies suggest that between 60% [<xref rid="R46" ref-type="bibr">46</xref>] and 95% [<xref rid="R45" ref-type="bibr">45</xref>] of people do not consume the recommended daily amounts of EPA+DHA either by dietary intake or by supplementation.</p>
                <p id="P40">Supplementing diets with EPA+DHA, long known for their anti-inflammatory effects, has been shown to improve symptoms and outcomes associated with some diseases common in aging that have an inflammatory component to their pathobiology (e.g., CVD, DM, arthritis) [<xref rid="R47" ref-type="bibr">47</xref>–<xref rid="R49" ref-type="bibr">49</xref>]. However, the mechanisms of action of EPA+DHA leading to inflammation reduction are not entirely known. Given that chronic low-grade systemic inflammation in aging is linked to multiple chronic diseases [<xref rid="R5" ref-type="bibr">5</xref>], that the adipokines leptin and adiponectin are involved in regulating inflammatory responses, and that some RCT findings suggest EPA+DHA supplementation may have beneficial effects on leptin and adiponectin, it is important to clarify the extent of the effects. It is also important to clarify the dose and duration of EPA+DHA supplementation required to affect a change, particularly in the LAR, a novel indicator of overall inflammatory status.</p>
              </sec>
              <sec id="S20">
                <label>4.2.</label>
                <title>Summary and comparison with other studies</title>
                <p id="P41">The primary purpose of this secondary data analysis was to determine the effects of supplementation with marine omega-3 fatty acids, EPA+DHA, on plasma levels of leptin and adiponectin in a sample of overweight and obese older adults with chronic inflammatory conditions. While supplementing diets with 2.5 g/d of EPA+DHA did not have a significant effect on plasma levels of leptin or adiponectin individually over the 8-week study interval, the mean LAR in the EPA+DHA group was reduced by 23% from week 4 to week 8. This is an important finding considering that emerging evidence suggests the LAR is an accurate indicator of systemic inflammation and risk for some inflammatory diseases in persons of all age groups [<xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref>]. Although normal reference values for LARs are not available to date, lower LARs have been shown to indicate less inflammation [<xref rid="R52" ref-type="bibr">52</xref>–<xref rid="R56" ref-type="bibr">56</xref>]. The current study finding of a 23% reduction in the LAR after EPA+DHA supplementation is aligned with a 2017 study by Jacobo-Cejudo et al. that assessed the effects of EPA+DHA supplementation (520 mg/d) on leptin and adiponectin over 24 weeks in 54 patients with DM [<xref rid="R57" ref-type="bibr">57</xref>]. In that study, individual levels of leptin and adiponectin did not change significantly over time, however, the LAR was reduced by 81.5% in the EPA+DHA treated group by the study end point compared to baseline. Future studies determining more definitive reference values for leptin, adiponectin, and the LAR in terms of inflammation status would significantly move this field of inquiry forward.</p>
                <p id="P42">The finding that no significant changes in plasma levels of leptin or adiponectin were detected in the EPA+DHA group or between the two groups in the current study is similar to findings reported by several previous RCTs in adult populations [<xref rid="R28" ref-type="bibr">28</xref>,<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R59" ref-type="bibr">59</xref>]. However, the EPA+DHA dose per day, study duration, and populations of interest varied across these studies. Previous studies that have reported significantly lower levels of leptin or higher levels of adiponectin after EPA+DHA supplementation used doses ranging from 1.244 – 4.2 g/d for longer periods of time (12 – 24 weeks) than the current study [<xref rid="R60" ref-type="bibr">60</xref>,<xref rid="R61" ref-type="bibr">61</xref>]. For example, in 2006 Krebs and colleagues tested EPA+DHA supplementation (4.2 g/d) for 24 weeks in a sample of 67 overweight women (BMI &gt; 27) with hyperinsulinemia and found significantly lower leptin levels and significantly higher adiponectin levels in the treatment group compared to the control group by the end of the study [<xref rid="R60" ref-type="bibr">60</xref>]. Taken together, the findings of these studies suggest that an EPA+DHA daily dose between ~1.2 and 4.2 g/d for at least 12 weeks may be necessary before significant beneficial changes to individual levels of leptin or adiponectin occur in overweight or obese older adults with inflammatory conditions.</p>
                <p id="P43">There were no differences in BMI between groups across the current study interval. However, both groups exhibited higher levels of leptin at the three study time points than the current reference values that are categorized by sex, age, and BMI (<xref rid="T6" ref-type="table">Table 6</xref>). Additionally, while the mean adiponectin levels at the three study time points in the EPA+DHA group were normal according to the reference values (for people with BMIs &gt; 30, (<xref rid="T6" ref-type="table">Table 6</xref>), the adiponectin levels in the control group were unusually high throughout the study compared to reference values (<xref rid="T7" ref-type="table">Table 7</xref>). Although the reasons for these variations are not clear, there are several factors known to influence leptin and adiponectin levels in addition to BMI [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R62" ref-type="bibr">62</xref>,<xref rid="R63" ref-type="bibr">63</xref>]. For example, the antidiabetic drug metformin has been shown to activate the AMPK pathway, leading to increased expression of adiponectin by adipocytes [<xref rid="R64" ref-type="bibr">64</xref>]. Metformin has also been shown to improve leptin sensitivity [<xref rid="R65" ref-type="bibr">65</xref>]. Further, a 2011 review of clinical studies evaluating the effects of antidiabetic drugs on leptin and adiponectin in patients with DM reported that insulin increased both leptin and adiponectin, orlistat decreased leptin and increased adiponectin, glimepiride increased adiponectin but had no effect on leptin, and fenofibrate decreased leptin but had no effect on adiponectin [<xref rid="R66" ref-type="bibr">66</xref>]. In the current study, there was no difference in frequency of use of metformin or insulin between groups. Data on the use of other antidiabetic drugs were not collected.</p>
                <p id="P44">The hormones testosterone, estrogen, and progesterone have also been reported to differentially affect leptin and adiponectin levels. Estrogen has been shown to upregulate pathways (PPAR-γ and AMPK) known to increase adipocyte production of leptin and adiponectin [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>] while testosterone has been shown to down-regulate leptin and adiponectin by inhibiting mRNA and protein expression in adipocytes [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R67" ref-type="bibr">67</xref>]. As a result, men tend to have lower levels of leptin and adiponectin than women. Nevertheless, we did not find significant differences in leptin or adiponectin levels between men and women in the current study. Further investigation is needed to clarify the extent sex hormones impact leptin and adiponectin.</p>
                <p id="P45">The strong negative correlations between adiponectin and IL-1β at week 4 and between adiponectin and TNF-α at week 8 in the EPA+DHA Group detected in the current study are congruent with reports from previous studies showing that adiponectin inhibits secretion of pro-inflammatory mediators by innate immune cells [<xref rid="R68" ref-type="bibr">68</xref>,<xref rid="R69" ref-type="bibr">69</xref>] and suggesting that adiponectin has anti-inflammatory actions [<xref rid="R61" ref-type="bibr">61</xref>,<xref rid="R70" ref-type="bibr">70</xref>–<xref rid="R72" ref-type="bibr">72</xref>]. Conversely, the significant negative relationship that emerged between leptin and TNF-α in the Control Group at week 8 differs from recent literature reporting that leptin upregulates TNF-α in innate immune cells [<xref rid="R71" ref-type="bibr">71</xref>,<xref rid="R73" ref-type="bibr">73</xref>]. The reasons for this unexpected relationship seen in the current study are unclear.</p>
                <p id="P46">The combined EPA+DHA dose used in our parent study was 2.5 g/d for a period of eight weeks. This dose and length of treatment aligned with recommendations that a dose of greater than 2 g/d is needed to elicit anti-inflammatory effects and that up to 3 g/d is safe for the general public to consume [<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R74" ref-type="bibr">74</xref>,<xref rid="R75" ref-type="bibr">75</xref>]. However, this dose and duration of supplementation had no significant effect on plasma levels of leptin and adiponectin individually in the current study. Some human studies using comparable doses have reported similar null findings in terms of the effect of EPA+DHA supplementation on leptin and adiponectin levels [<xref rid="R58" ref-type="bibr">58</xref>,<xref rid="R76" ref-type="bibr">76</xref>–<xref rid="R80" ref-type="bibr">80</xref>]. Thus, a larger dose of EPA+DHA or a similar dose for a longer period of time may be necessary to affect a significant change in these individual adipokine levels, a hypothesis supported by previous RCTs reporting that EPA+DHA supplementation for 10 to 24 weeks leads to beneficial changes in leptin, adiponectin, or LARs in some populations [<xref rid="R57" ref-type="bibr">57</xref>,<xref rid="R60" ref-type="bibr">60</xref>,<xref rid="R61" ref-type="bibr">61</xref>,<xref rid="R81" ref-type="bibr">81</xref>–<xref rid="R84" ref-type="bibr">84</xref>].</p>
                <p id="P47">No side effects or adverse events associated with EPA+DHA supplementation were reported in the parent study, which is in line with a recent systematic review of RCTs evaluating the incidence of side effects in 27 studies testing EPA+DHA supplementation [<xref rid="R85" ref-type="bibr">85</xref>]. The review concluded that the most commonly reported side effect was mild gastrointestinal disturbances, occurring in only 3.5% of all people randomized to the EPA+DHA groups in the included studies [<xref rid="R85" ref-type="bibr">85</xref>]. Additionally, there were no side effects or adverse events associated with the mineral oil placebo in the parent study. The potential for unintended effects of the comparator oil (e.g. mineral oil) on outcomes is a legitimate concern in lipid supplementation studies. In a recent review of 80 studies that used mineral oil as a placebo, researchers found lack of evidence that mineral oil significantly affected inflammatory markers [<xref rid="R86" ref-type="bibr">86</xref>]. While there has been concern that some of the positive results associated with icosapent ethyl (a type of n-3 fatty acid) in the Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial (REDUCE-IT) were due to the potentially negative effects of the mineral oil placebo, after a review of the literature, authors concluded that mineral oil, in quantities typically used for placebos in clinical trials, does not notably impact study outcomes [<xref rid="R86" ref-type="bibr">86</xref>]. This increases confidence that results seen in the parent study and our analysis are related to EPA+DHA supplementation.</p>
              </sec>
              <sec id="S21">
                <label>4.3.</label>
                <title>Strengths and limitations</title>
                <p id="P49">The current study had several strengths. First, the parent study was a RCT, the gold standard for determining cause and effect relationships. Additionally, the combined EPA+DHA dose of 2.5 g/d was aligned with the literature reporting that at least 2 g/d is needed to elicit anti-inflammatory effects [<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R87" ref-type="bibr">87</xref>]. Finally, this study evaluated the effects of the intervention on the LAR, which, to our knowledge, has been done in only one previous study according to a recent systematic review of RCTs testing the effects of EPA+DHA supplementation on leptin and adiponectin [<xref rid="R88" ref-type="bibr">88</xref>].</p>
                <p id="P50">A limitation of this study is that because it was a secondary analysis of an existing data set, potential covariates such as estrogen or testosterone were not considered in the statistical analysis because they were not measured in the parent study. A second limitation is the relatively small sample size that may have reduced our ability to find a statistical effect in the sample if the effect exists in the population. Testing the intervention in a larger sample for a longer period of time may lead to different findings.</p>
              </sec>
              <sec id="S22">
                <label>4.4.</label>
                <title>Conclusion</title>
                <p id="P51">The current study evaluated the effects of EPA+DHA oral supplementation on plasma levels of leptin, adiponectin, and the LAR in a sample of overweight and obese older adults with chronic inflammatory conditions. We hypothesized that EPA+DHA oral therapy would have beneficial effects on plasma levels of leptin and adiponectin, adipokines involved in modulating inflammatory responses. While we report no significant effects of EPA+DHA supplementation on levels of leptin or adiponectin individually, there was a trend toward a reduction in the LAR (by 23%) between weeks 4 and 8 among the EPA+DHA group. Future studies using larger samples, high versus low dose EPA+DHA, and perhaps variable ratios of EPA to DHA for longer treatment periods are needed to make clear the extent that EPA+DHA supplementation alters leptin, adiponectin, and the LAR.</p>
              </sec>
            </sec>
          </body>
          <back>
            <ack id="S23">
              <title>Funding</title>
              <p id="P52">This paper presents independent research funded by The Robert Wood Johnson Foundation (RWJF), Future of Nursing Scholars (FNS) program in collaboration with The Ohio State University (OSU). The parent study was funded by the National Institute of Nursing Research (NINR) of the National Institutes of Health (NIH) (R21NR012803); and the Clinical and Translational Science Award (UL1TR001070). This paper was completed without input from funders. Views expressed are of the authors and not necessarily those of RWJF FNS, OSU, NINR, or NIH.</p>
            </ack>
            <fn-group>
              <fn id="FN12">
                <p id="P53">Data</p>
                <p id="P54">The data used in this work are not available for public use. For information on data sharing contact the corresponding author.</p>
              </fn>
              <fn fn-type="COI-statement" id="FN13">
                <p id="P55">Declaration of Competing Interest</p>
                <p id="P56">Authors declare there are no conflicts of interest concerning this manuscript.</p>
              </fn>
            </fn-group>
            <glossary>
              <title>Abbreviations</title>
              <def-list>
                <def-item>
                  <term>BMI</term>
                  <def>
                    <p id="P57">body mass index</p>
                  </def>
                </def-item>
                <def-item>
                  <term>CVD</term>
                  <def>
                    <p id="P58">cardiovascular disease</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DHA</term>
                  <def>
                    <p id="P59">docosahexaenoic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term>DM</term>
                  <def>
                    <p id="P60">diabetes mellitus</p>
                  </def>
                </def-item>
                <def-item>
                  <term>EPA</term>
                  <def>
                    <p id="P61">eicosapentaenoic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term>IL</term>
                  <def>
                    <p id="P62">interleukin</p>
                  </def>
                </def-item>
                <def-item>
                  <term>LAR</term>
                  <def>
                    <p id="P63">leptin-to-adiponectin ratio</p>
                  </def>
                </def-item>
                <def-item>
                  <term>mRNA</term>
                  <def>
                    <p id="P64">messenger ribonucleic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term>TNF</term>
                  <def>
                    <p id="P65">tumor necrosis factor</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>[1]</label>
                <mixed-citation publication-type="journal"><name><surname>Zuo</surname><given-names>L</given-names></name>, <name><surname>Prather</surname><given-names>ER</given-names></name>, <name><surname>Stetskiv</surname><given-names>M</given-names></name>, <name><surname>Garrison</surname><given-names>DE</given-names></name>, <name><surname>Meade</surname><given-names>JR</given-names></name>, <name><surname>Peace</surname><given-names>TI</given-names></name>, <name><surname>Zhou</surname><given-names>T</given-names></name>, <article-title>Inflammaging and oxidative stress in human diseases: from molecular mechanisms to novel treatments</article-title>, <source>Int J Mol. Sci</source><volume>20</volume> (<year>2019</year>), <pub-id pub-id-type="doi">10.3390/ijms20184472</pub-id>.</mixed-citation>
              </ref>
              <ref id="R2">
                <label>[2]</label>
                <mixed-citation publication-type="journal"><name><surname>Bektas</surname><given-names>Schurman</given-names></name>, <name><surname>Sen</surname><given-names>Ferrucci</given-names></name>, <article-title>Aging, inflammation and the environment</article-title>, <source>Exp. Gerontol</source> (<year>2017</year>). <pub-id pub-id-type="doi">10.1016/j.exger.2017.12.015</pub-id>.</mixed-citation>
              </ref>
              <ref id="R3">
                <label>[3]</label>
                <mixed-citation publication-type="journal"><name><surname>Calçada</surname><given-names>D</given-names></name>, <name><surname>Vianello</surname><given-names>D</given-names></name>, <name><surname>Giampieri</surname><given-names>E</given-names></name>, <name><surname>Sala</surname><given-names>C</given-names></name>, <name><surname>Castellani</surname><given-names>G</given-names></name>, <name><surname>de Graaf</surname><given-names>A</given-names></name>, <name><surname>Kremer</surname><given-names>B</given-names></name>, <name><surname>van Ommen</surname><given-names>B</given-names></name>, <name><surname>Feskens</surname><given-names>E</given-names></name>, <name><surname>Santoro</surname><given-names>A</given-names></name>, <name><surname>Franceschi</surname><given-names>C</given-names></name>, <name><surname>Bouwman</surname><given-names>J</given-names></name>, <article-title>The role of low-grade inflammation and metabolic flexibility in aging and nutritional modulation thereof: a systems biology approach</article-title>, <source>Mech. Agei. Dev</source><volume>136–137</volume> (<year>2014</year>) <fpage>138</fpage>–<lpage>147</lpage>, <pub-id pub-id-type="doi">10.1016/j.mad.2014.01.004</pub-id>.</mixed-citation>
              </ref>
              <ref id="R4">
                <label>[4]</label>
                <mixed-citation publication-type="journal"><name><surname>Calder</surname><given-names>PC</given-names></name>, <name><surname>Bosco</surname><given-names>N</given-names></name>, <name><surname>Bourdet-Sicard</surname><given-names>R</given-names></name>, <name><surname>Capuron</surname><given-names>L</given-names></name>, <name><surname>Delzenne</surname><given-names>N</given-names></name>, <name><surname>Doré</surname><given-names>J</given-names></name>, <name><surname>Franceschi</surname><given-names>C</given-names></name>, <name><surname>Lehtinen</surname><given-names>MJ</given-names></name>, <name><surname>Recker</surname><given-names>T</given-names></name>, <name><surname>Salvioli</surname><given-names>S</given-names></name>, <name><surname>Visioli</surname><given-names>F</given-names></name>, <article-title>Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition</article-title>, <source>Agei. Res. Rev</source><volume>40</volume> (<year>2017</year>) <fpage>95</fpage>–<lpage>119</lpage>, <pub-id pub-id-type="doi">10.1016/j.arr.2017.09.001</pub-id>.</mixed-citation>
              </ref>
              <ref id="R5">
                <label>[5]</label>
                <mixed-citation publication-type="journal"><name><surname>Ferrucci</surname><given-names>L</given-names></name>, <name><surname>Fabbri</surname><given-names>E</given-names></name>, <article-title>Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty</article-title>, <source>Nat. Rev Cardiol</source><volume>15</volume> (<year>2018</year>) <fpage>505</fpage>–<lpage>522</lpage>, <pub-id pub-id-type="doi">10.1038/s41569-018-0064-2</pub-id>.<pub-id pub-id-type="pmid">30065258</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>[6]</label>
                <mixed-citation publication-type="journal"><name><surname>Franceschi</surname><given-names>C</given-names></name>, <name><surname>Bonafè</surname><given-names>M</given-names></name>, <name><surname>Valensin</surname><given-names>S</given-names></name>, <name><surname>Olivieri</surname><given-names>F</given-names></name>, <name><surname>De Luca</surname><given-names>M</given-names></name>, <name><surname>Ottaviani</surname><given-names>E</given-names></name>, <name><surname>De Benedictis</surname><given-names>G</given-names></name>, <article-title>Inflamm-aging. an evolutionary perspective on immunosenescence</article-title>, <source>Ann. N Y Acad. Sci</source><volume>908</volume> (<year>2000</year>) <fpage>244</fpage>–<lpage>254</lpage>, <pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb06651.x</pub-id>.<pub-id pub-id-type="pmid">10911963</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>[7]</label>
                <mixed-citation publication-type="book"><name><surname>Dagogo-Jack</surname></name>, <source>Leptin Regulation and Clinical Applications</source>, <publisher-name>Springer International Publishing</publisher-name>, <publisher-loc>Cham</publisher-loc>, <year>2015</year>.</mixed-citation>
              </ref>
              <ref id="R8">
                <label>[8]</label>
                <mixed-citation publication-type="journal"><name><surname>Ghantous</surname><given-names>Azrak</given-names></name>, <name><surname>Hanache</surname><given-names>Abou-Kheir</given-names></name>, <name><surname>Zeidan</surname></name>, <article-title>Differential role of leptin and adiponectin in cardiovascular system</article-title>, <source>Int. J. Endocrinol</source> (<year>2015</year>), <fpage>534320</fpage>, <pub-id pub-id-type="doi">10.1155/2015/534320</pub-id>.<pub-id pub-id-type="pmid">26064110</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>[9]</label>
                <mixed-citation publication-type="book">ed. <source>Litwack, Adiponectin</source>, <publisher-name>Elsevier/Academic Press</publisher-name>, <publisher-loc>London; Waltham, MA</publisher-loc>, <year>2012</year>.</mixed-citation>
              </ref>
              <ref id="R10">
                <label>[10]</label>
                <mixed-citation publication-type="journal"><name><surname>Martyniak</surname><given-names>K</given-names></name>, <name><surname>Masternak</surname><given-names>MM</given-names></name>, <article-title>Changes in adipose tissue cellular composition during obesity and aging as a cause of metabolic dysregulation</article-title>, <source>Exp. Gerontol</source><volume>94</volume> (<year>2017</year>) <fpage>59</fpage>–<lpage>63</lpage>, <pub-id pub-id-type="doi">10.1016/j.exger.2016.12.007</pub-id>.<pub-id pub-id-type="pmid">27939445</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>[11]</label>
                <mixed-citation publication-type="journal"><name><surname>Murray</surname><given-names>ET</given-names></name>, <name><surname>Hardy</surname><given-names>R</given-names></name>, <name><surname>Hughes</surname><given-names>A</given-names></name>, <name><surname>Wills</surname><given-names>A</given-names></name>, <name><surname>Sattar</surname><given-names>N</given-names></name>, <name><surname>Deanfield</surname><given-names>J</given-names></name>, <name><surname>Kuh</surname><given-names>D</given-names></name>, <name><surname>Whincup</surname><given-names>P</given-names></name>, <article-title>Overweight across the life course and adipokines, inflammatory and endothelial markers at age 60–64 years: evidence from the 1946 birth cohort</article-title>, <source>Int. J Obes. (Lond)</source><volume>39</volume> (<year>2015</year>) <fpage>1010</fpage>–<lpage>1018</lpage>, <pub-id pub-id-type="doi">10.1038/ijo.2015.19</pub-id>.<pub-id pub-id-type="pmid">25676237</pub-id></mixed-citation>
              </ref>
              <ref id="R12">
                <label>[12]</label>
                <mixed-citation publication-type="journal"><name><surname>Gairolla</surname><given-names>Kler</given-names></name>, <name><surname>Modi</surname><given-names>Khurana</given-names></name>, <article-title>Leptin and adiponectin: pathophysiological role and possible therapeutic target of inflammation in ischemic stroke</article-title>, <source>Rev. Neurosci</source><volume>28</volume> (<year>2017</year>) <fpage>295</fpage>–<lpage>306</lpage>, <pub-id pub-id-type="doi">10.1515/revneuro-2016-0055</pub-id>.<pub-id pub-id-type="pmid">28121618</pub-id></mixed-citation>
              </ref>
              <ref id="R13">
                <label>[13]</label>
                <mixed-citation publication-type="journal"><name><surname>Pérez-Pérez</surname><given-names>A</given-names></name>, <name><surname>Sánchez-Jiménez</surname><given-names>F</given-names></name>, <name><surname>Vilariño-García</surname><given-names>T</given-names></name>, <name><surname>Sánchez-Margalet</surname><given-names>V</given-names></name>, <article-title>Role of leptin in inflammation and vice versa</article-title>, <source>IJMS</source><volume>21</volume> (<year>2020</year>) <fpage>5887</fpage>, <pub-id pub-id-type="doi">10.3390/ijms21165887</pub-id>.</mixed-citation>
              </ref>
              <ref id="R14">
                <label>[14]</label>
                <mixed-citation publication-type="journal"><name><surname>Franceschi</surname><given-names>Campisi</given-names></name>, <article-title>Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases</article-title>, <source>J. Gerontol. A Biol. Sci. Med. Sci</source><volume>69</volume> (<issue>Suppl 1</issue>) (<year>2014</year>) <fpage>S4</fpage>–<lpage>S9</lpage>, <pub-id pub-id-type="doi">10.1093/gerona/glu057</pub-id>.<pub-id pub-id-type="pmid">24833586</pub-id></mixed-citation>
              </ref>
              <ref id="R15">
                <label>[15]</label>
                <mixed-citation publication-type="journal"><name><surname>Ouchi</surname><given-names>Walsh</given-names></name>, <article-title>Adiponectin as an anti-inflammatory factor</article-title>, <source>Clinic. Chimic. Acta</source><volume>380</volume> (<year>2007</year>) <fpage>24</fpage>–<lpage>30</lpage>, <pub-id pub-id-type="doi">10.1016/j.cca.2007.01.026</pub-id>.</mixed-citation>
              </ref>
              <ref id="R16">
                <label>[16]</label>
                <mixed-citation publication-type="journal"><name><surname>Ajuwon</surname><given-names>KM</given-names></name>, <name><surname>Spurlock</surname><given-names>ME</given-names></name>, <article-title>Adiponectin inhibits lps-induced nf-κb activation and il-6 production and increases pparγ2 expression in adipocytes</article-title>, <source>Am. J. Physiology-Regulatory, Integra. Comparative Physiol</source><volume>288</volume> (<year>2005</year>) <fpage>R1220</fpage>–<lpage>R1225</lpage>, <pub-id pub-id-type="doi">10.1152/ajpregu.00397.2004</pub-id>.</mixed-citation>
              </ref>
              <ref id="R17">
                <label>[17]</label>
                <mixed-citation publication-type="journal"><name><surname>Manigrasso</surname><given-names>MR</given-names></name>, <name><surname>Ferroni</surname><given-names>P</given-names></name>, <name><surname>Santilli</surname><given-names>F</given-names></name>, <name><surname>Taraborelli</surname><given-names>T</given-names></name>, <name><surname>Guagnano</surname><given-names>MT</given-names></name>, <name><surname>Michetti</surname><given-names>N</given-names></name>, <name><surname>Davì</surname><given-names>G</given-names></name>, <article-title>Association between circulating adiponectin and interleukin-10 levels in android obesity: effects of weight loss</article-title>, <source>J.Clin. Endocrinol. Metabol</source><volume>90</volume> (<year>2005</year>) <fpage>5876</fpage>–<lpage>5879</lpage>, <pub-id pub-id-type="doi">10.1210/jc.2005-0281</pub-id>.</mixed-citation>
              </ref>
              <ref id="R18">
                <label>[18]</label>
                <mixed-citation publication-type="journal"><name><surname>Frühbeck</surname><given-names>G</given-names></name>, <name><surname>Catalán</surname><given-names>V</given-names></name>, <name><surname>Rodríguez</surname><given-names>A</given-names></name>, <name><surname>Gómez-Ambrosi</surname><given-names>J</given-names></name>, <article-title>Adiponectin-leptin ratio: a promising index to estimate adipose tissue dysfunction. relation with obesity-associated cardiometabolic risk</article-title>, <source>Adipoc</source><volume>7</volume> (<year>2018</year>) <fpage>57</fpage>–<lpage>62</lpage>, <pub-id pub-id-type="doi">10.1080/21623945.2017.1402151</pub-id>.</mixed-citation>
              </ref>
              <ref id="R19">
                <label>[19]</label>
                <mixed-citation publication-type="journal"><name><surname>Golbahar</surname><given-names>Das</given-names></name>, <name><surname>Al-Ayadhi</surname><given-names>Gumaa</given-names></name>, <article-title>Leptin-to-adiponectin, adiponectin-to-leptin ratios, and insulin are specific and sensitive markers associated with polycystic ovary syndrome: a case-control study from bahrain</article-title>, <source>Metab. Syndr. Relat. Disord</source><volume>10</volume> (<year>2012</year>) <fpage>98</fpage>–<lpage>102</lpage>, <pub-id pub-id-type="doi">10.1089/met.2011.0075</pub-id>.<pub-id pub-id-type="pmid">22107332</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>[20]</label>
                <mixed-citation publication-type="journal"><name><surname>Lekva</surname><given-names>Michelsen</given-names></name>, <name><surname>Aukrust</surname><given-names>Henriksen</given-names></name>, <name><surname>Bollerslev</surname><given-names>Ueland</given-names></name>, <article-title>Leptin and adiponectin as predictors of cardiovascular risk after gestational diabetes mellitus</article-title>, <source>Cardiovasc. Diabetol</source><volume>16</volume> (<year>2017</year>) <fpage>5</fpage>, <pub-id pub-id-type="doi">10.1186/s12933-016-0492-4</pub-id>.<pub-id pub-id-type="pmid">28068986</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>[21]</label>
                <mixed-citation publication-type="journal"><name><surname>Sarray</surname><given-names>Madan</given-names></name>, <name><surname>Saleh</surname><given-names>Mahmoud</given-names></name>, <article-title>Almawi, Validity of adiponectin-to-leptin and adiponectin-to-resistin ratios as predictors of polycystic ovary syndrome</article-title>, <source>Fertil. Steril</source><volume>104</volume> (<year>2015</year>) <fpage>460</fpage>–<lpage>466</lpage>, <pub-id pub-id-type="doi">10.1016/j.fertnstert.2015.05.007</pub-id>.<pub-id pub-id-type="pmid">26051098</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>[22]</label>
                <mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>Chen</given-names></name>, <name><surname>Chiu</surname><given-names>Lin</given-names></name>, <name><surname>Li</surname><given-names>Lu</given-names></name>, <article-title>Leptin/adiponectin ratio as a potential biomarker for metabolic syndrome in patients with schizophrenia</article-title>, <source>Psychoneuroendocrinol</source><volume>92</volume> (<year>2018</year>) <fpage>34</fpage>–<lpage>40</lpage>, <pub-id pub-id-type="doi">10.1016/j.psyneuen.2018.03.021</pub-id>.</mixed-citation>
              </ref>
              <ref id="R23">
                <label>[23]</label>
                <mixed-citation publication-type="journal"><name><surname>Drevon</surname></name>, <article-title>Fatty acids and expression of adipokines</article-title>, <source>Biochim. Biophys. Acta</source><volume>1740</volume> (<year>2005</year>) <fpage>287</fpage>–<lpage>292</lpage>, <pub-id pub-id-type="doi">10.1016/j.bbadis.2004.11.019</pub-id>.<pub-id pub-id-type="pmid">15949695</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>[24]</label>
                <mixed-citation publication-type="journal"><name><surname>Flachs</surname><given-names>Mohamed-Ali</given-names></name>, <name><surname>Horakova</surname><given-names>Rossmeisl</given-names></name>, <name><surname>Hosseinzadeh-Attar</surname><given-names>Hensler</given-names></name>, <name><surname>Kopecky</surname><given-names>Ruzickova</given-names></name>, <article-title>Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet</article-title>, <source>Diabetolog</source><volume>49</volume> (<year>2006</year>) <fpage>394</fpage>–<lpage>397</lpage>, <pub-id pub-id-type="doi">10.1007/s00125-005-0053-y</pub-id>.</mixed-citation>
              </ref>
              <ref id="R25">
                <label>[25]</label>
                <mixed-citation publication-type="journal"><name><surname>Lombardo</surname><given-names>Hein</given-names></name>, <article-title>Chicco, metabolic syndrome: effects of n-3 pufas on a model of dyslipidemia, insulin resistance and adiposity</article-title>, <source>Lip</source><volume>42</volume> (<year>2007</year>) <fpage>427</fpage>–<lpage>437</lpage>, <pub-id pub-id-type="doi">10.1007/s11745-007-3039-3</pub-id>.</mixed-citation>
              </ref>
              <ref id="R26">
                <label>[26]</label>
                <mixed-citation publication-type="journal"><name><surname>Selenscig</surname><given-names>Rossi</given-names></name>, <name><surname>Chicco</surname><given-names>Lombardo</given-names></name>, <article-title>Increased leptin storage with altered leptin secretion from adipocytes of rats with sucrose-induced dyslipidemia and insulin resistance: effect of dietary fish oil</article-title>, <source>Metab. Clin. Exp</source><volume>59</volume> (<year>2010</year>) <fpage>787</fpage>–<lpage>795</lpage>, <pub-id pub-id-type="doi">10.1016/j.metabol.2009.09.025</pub-id>.<pub-id pub-id-type="pmid">20005540</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>[27]</label>
                <mixed-citation publication-type="journal"><name><surname>Itariu</surname><given-names>Zeyda</given-names></name>, <name><surname>Hochbrugger</surname><given-names>Neuhofer</given-names></name>, <name><surname>Prager</surname><given-names>Schindler</given-names></name>, <name><surname>Bohdjalian</surname><given-names>Mascher</given-names></name>, <name><surname>Vangala</surname><given-names>Schranz</given-names></name>, <name><surname>Krebs</surname><given-names>Bischof</given-names></name>, <article-title>Stulnig, long-chain n-3 pufas reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial</article-title>, <source>Am. J. Clin. Nutr</source><volume>96</volume> (<year>2012</year>) <fpage>1137</fpage>–<lpage>1149</lpage>, <pub-id pub-id-type="doi">10.3945/ajcn.112.037432</pub-id>.<pub-id pub-id-type="pmid">23034965</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>[28]</label>
                <mixed-citation publication-type="journal"><name><surname>Poreba</surname><given-names>Mostowik</given-names></name>, <name><surname>Siniarski</surname><given-names>Golebiowska-Wiatrak</given-names></name>, <name><surname>Malinowski</surname><given-names>Haberka</given-names></name>, <name><surname>Konduracka</surname><given-names>Nessler</given-names></name>, <name><surname>Undas</surname><given-names>Gajos</given-names></name>, <article-title>Treatment with high-dose n-3 pufas has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes</article-title>, <source>Cardiovasc. Diabetol</source><volume>16</volume> (<year>2017</year>), <pub-id pub-id-type="doi">10.1186/s12933-017-0523-9</pub-id>.</mixed-citation>
              </ref>
              <ref id="R29">
                <label>[29]</label>
                <mixed-citation publication-type="journal"><name><surname>Huerta</surname><given-names>Prieto-Hontoria</given-names></name>, <name><surname>Sainz</surname><given-names>Martinez</given-names></name>, <name><surname>Moreno-Aliaga</surname></name>, <article-title>Supplementation with alpha-lipoic acid alone or in combination with eicosapentaenoic acid modulates the inflammatory status of healthy overweight or obese women consuming an energy-restricted diet</article-title>, <source>J. Nutr</source><volume>146</volume> (<year>2016</year>) <fpage>889S</fpage>–<lpage>896S</lpage>, <pub-id pub-id-type="doi">10.3945/jn.115.224105</pub-id>.</mixed-citation>
              </ref>
              <ref id="R30">
                <label>[30]</label>
                <mixed-citation publication-type="journal"><name><surname>Banga</surname><given-names>Unal</given-names></name>, <name><surname>Tripathi</surname><given-names>Pokrovskaya</given-names></name>, <name><surname>Owens</surname><given-names>Kern</given-names></name>, <article-title>Ranganathan, Adiponectin translation is increased by the ppargamma agonists pioglitazone and omega-3 fatty acids</article-title>, <source>Am. J. Physiol. Endocrinol. Metab</source><volume>296</volume> (<year>2009</year>) <fpage>E480</fpage>–<lpage>E489</lpage>, <pub-id pub-id-type="doi">10.1152/ajpendo.90892.2008</pub-id>.<pub-id pub-id-type="pmid">19088251</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>[31]</label>
                <mixed-citation publication-type="journal"><name><surname>Calder</surname></name>, <article-title>Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance</article-title>, <source>Biochim. Biophys. Acta</source><volume>1851</volume> (<year>2015</year>) <fpage>469</fpage>–<lpage>484</lpage>, <pub-id pub-id-type="doi">10.1016/j.bbalip.2014.08.010</pub-id>.<pub-id pub-id-type="pmid">25149823</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>[32]</label>
                <mixed-citation publication-type="journal"><name><surname>Harris</surname></name>, <article-title>The omega-3 index as a risk factor for coronary heart disease</article-title>, <source>Am. J. Clin. Nutr</source><volume>87</volume> (<year>2008</year>) <fpage>1997S</fpage>–<lpage>2002S</lpage>, <pub-id pub-id-type="doi">10.1093/ajcn/87.6.1997S</pub-id>.<pub-id pub-id-type="pmid">18541601</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>[33]</label>
                <mixed-citation publication-type="journal"><name><surname>Tan</surname><given-names>A</given-names></name>, <name><surname>Sullenbarger</surname><given-names>B</given-names></name>, <name><surname>Prakash</surname><given-names>R</given-names></name>, <name><surname>McDaniel</surname><given-names>JC</given-names></name>, <article-title>Supplementation with eicosapentaenoic acid and docosahexaenoic acid reduces high levels of circulating proinflammatory cytokines in aging adults: a randomized, controlled study</article-title>, <source>Prostagl, Leukot. Essent. Fat, Acids</source><volume>132</volume> (<year>2018</year>) <fpage>23</fpage>–<lpage>29</lpage>, <pub-id pub-id-type="doi">10.1016/j.plefa.2018.03.010</pub-id>.</mixed-citation>
              </ref>
              <ref id="R34">
                <label>[34]</label>
                <mixed-citation publication-type="journal"><name><surname>McDaniel</surname><given-names>Belury</given-names></name>, <name><surname>Ahijevych</surname><given-names>Blakely</given-names></name>, <article-title>Omega-3 fatty acids effect on wound healing</article-title>, <source>Wou. Repa. Regen</source><volume>16</volume> (<year>2008</year>) <fpage>337</fpage>–<lpage>345</lpage>, <pub-id pub-id-type="doi">10.1111/j.1524-475X.2008.00388.x</pub-id>.</mixed-citation>
              </ref>
              <ref id="R35">
                <label>[35]</label>
                <mixed-citation publication-type="journal"><name><surname>Calder</surname></name>, <article-title>Fatty acids and inflammation: the cutting edge between food and pharma</article-title>, <source>Eur. J. Pharmacol</source><volume>668</volume> (<issue>Suppl 1</issue>) (<year>2011</year>) <fpage>S50</fpage>–<lpage>S58</lpage>, <pub-id pub-id-type="doi">10.1016/j.ejphar.2011.05.085</pub-id>.<pub-id pub-id-type="pmid">21816146</pub-id></mixed-citation>
              </ref>
              <ref id="R36">
                <label>[36]</label>
                <mixed-citation publication-type="journal"><name><surname>Grenon</surname><given-names>Owens</given-names></name>, <name><surname>Nosova</surname><given-names>Hughes-Fulford</given-names></name>, <name><surname>Alley</surname><given-names>Chong</given-names></name>, <name><surname>Perez</surname><given-names>Yen</given-names></name>, <name><surname>Boscardin</surname><given-names>Hellmann</given-names></name>, <name><surname>Spite</surname><given-names>Conte</given-names></name>, <article-title>Short-Term, high-dose fish oil supplementation increases the production of omega-3 fatty acid-derived mediators in patients with peripheral artery disease (the omega-pad i trial)</article-title>, <source>J. Am. Heart Assoc</source><volume>4</volume> (<year>2015</year>), <fpage>e002034</fpage>, <pub-id pub-id-type="doi">10.1161/JAHA.115.002034</pub-id>.<pub-id pub-id-type="pmid">26296857</pub-id></mixed-citation>
              </ref>
              <ref id="R37">
                <label>[37]</label>
                <mixed-citation publication-type="book"><collab>U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Nutritional Products Labeling and Dietary Supplements (FDA/CSFAN)</collab>, <source>FDA Announces New Qualified Health Claims for EPA and DHA Omega-3 Consumption and the Risk of Hypertension and Coronary Heart Disease</source>, <publisher-name>FDA</publisher-name>, <year>2019</year>.</mixed-citation>
              </ref>
              <ref id="R38">
                <label>[38]</label>
                <mixed-citation publication-type="journal"><name><surname>McDaniel</surname><given-names>Massey</given-names></name>, <name><surname>Nicolaou</surname></name>, <article-title>Fish oil supplementation alters levels of lipid mediators of inflammation in microenvironment of acute human wounds</article-title>, <source>Wou. Repa. Regen</source><volume>19</volume> (<year>2011</year>) <fpage>189</fpage>–<lpage>200</lpage>, <pub-id pub-id-type="doi">10.1111/j.1524-475X.2010.00659.x</pub-id>.</mixed-citation>
              </ref>
              <ref id="R39">
                <label>[39]</label>
                <mixed-citation publication-type="journal"><name><surname>Harris</surname><given-names>Taylor</given-names></name>, <name><surname>Thielke</surname><given-names>Payne</given-names></name>, <name><surname>Gonzalez</surname><given-names>Conde</given-names></name>, <article-title>Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research informatics support</article-title>, <source>J. Biomed. Inform</source><volume>42</volume> (<year>2009</year>) <fpage>377</fpage>–<lpage>381</lpage>, <pub-id pub-id-type="doi">10.1016/j.jbi.2008.08.010</pub-id>.<pub-id pub-id-type="pmid">18929686</pub-id></mixed-citation>
              </ref>
              <ref id="R40">
                <label>[40]</label>
                <mixed-citation publication-type="webpage"><collab>Meso Scale Discovery</collab>, <source>V-PLEX Human Leptin Kit</source>, (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://www.mesoscale.com/en/products/v-plex-human-leptin-kit-k151v5d/" ext-link-type="uri">https://www.mesoscale.com/en/products/v-plex-human-leptin-kit-k151v5d/</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 4, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R41">
                <label>[41]</label>
                <mixed-citation publication-type="webpage"><collab>Meso Scale Discovery</collab>, <source>R-PLEX Human Adiponectin Antibody Set</source>, (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://www.mesoscale.com/en/products/r-plex-human-adiponectin-antibody-set-f21yt/" ext-link-type="uri">https://www.mesoscale.com/en/products/r-plex-human-adiponectin-antibody-set-f21yt/</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 4, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R42">
                <label>[42]</label>
                <mixed-citation publication-type="journal"><name><surname>Quehenberger</surname><given-names>O</given-names></name>, <name><surname>Armando</surname><given-names>AM</given-names></name>, <name><surname>Dennis</surname><given-names>EA</given-names></name>, <article-title>High sensitivity quantitative lipidomics analysis of fatty acids in biological samples by gas chromatography-mass spectrometry</article-title>, <source>Biochim. Biophys. Acta</source><volume>1811</volume> (<year>2011</year>) <fpage>648</fpage>–<lpage>656</lpage>, <pub-id pub-id-type="doi">10.1016/j.bbalip.2011.07.006</pub-id>.<pub-id pub-id-type="pmid">21787881</pub-id></mixed-citation>
              </ref>
              <ref id="R43">
                <label>[43]</label>
                <mixed-citation publication-type="journal"><name><surname>Templeton</surname><given-names>A</given-names></name><article-title>two-step approach for transforming continuous variables to normal: implications and recommendations for is research</article-title>, <source>Commu. Assoc. Info. Systems</source><volume>28</volume> (<year>2011</year>), <pub-id pub-id-type="doi">10.17705/1CAIS.02804</pub-id>.</mixed-citation>
              </ref>
              <ref id="R44">
                <label>[44]</label>
                <mixed-citation publication-type="book"><name><surname>Bibus</surname><given-names>Raatz</given-names></name> (Ed.), <source>Fish and Fish Oil in Health and Disease Prevention</source>, <publisher-name>Elsevier/Academic Press</publisher-name>, <publisher-loc>Amsterdam</publisher-loc>, <year>2016</year>.</mixed-citation>
              </ref>
              <ref id="R45">
                <label>[45]</label>
                <mixed-citation publication-type="journal"><name><surname>Thompson</surname><given-names>Hein</given-names></name>, <name><surname>Hanson</surname><given-names>Smith</given-names></name>, <name><surname>Anderson-Berry</surname><given-names>Richter</given-names></name>, <name><surname>Bisselou</surname><given-names>Stessy</given-names></name>, <name><surname>Appiah</surname><given-names>Kusi</given-names></name>, <article-title>Kris-Etherton, skulas-ray, nordgren, omega-3 fatty acid intake by age, gender, and pregnancy status in the united states: national health and nutrition examination survey 2003–2014</article-title>, <source>Nutrie</source><volume>11</volume> (<year>2019</year>), <pub-id pub-id-type="doi">10.3390/nu11010177</pub-id>.</mixed-citation>
              </ref>
              <ref id="R46">
                <label>[46]</label>
                <mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Fulgoni</surname><given-names>VL</given-names></name>, <name><surname>Kris-Etherton</surname><given-names>PM</given-names></name>, <name><surname>Mitmesser</surname><given-names>SH</given-names></name>, <article-title>Dietary intakes of epa and dha omega-3 fatty acids among us childbearing-age and pregnant women: an analysis of nhanes 2001–2014</article-title>, <source>Nutrie</source><volume>10</volume> (<year>2018</year>), <pub-id pub-id-type="doi">10.3390/nu10040416</pub-id>.</mixed-citation>
              </ref>
              <ref id="R47">
                <label>[47]</label>
                <mixed-citation publication-type="webpage"><collab>Centers for Disease Control</collab>, <source>FastStats Heart Disease</source>, (<year>2020</year>). <comment><ext-link xlink:href="https://www.cdc.gov/nchs/fastats/heart-disease.htm" ext-link-type="uri">https://www.cdc.gov/nchs/fastats/heart-disease.htm</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>January 25, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R48">
                <label>[48]</label>
                <mixed-citation publication-type="webpage"><collab>Centers for Disease Control</collab>, <source>FastStats Diabetes</source>, (<year>2020</year>). <comment><ext-link xlink:href="https://www.cdc.gov/nchs/fastats/diabetes.htm" ext-link-type="uri">https://www.cdc.gov/nchs/fastats/diabetes.htm</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>January 25, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R49">
                <label>[49]</label>
                <mixed-citation publication-type="webpage"><collab>Centers for Disease Control</collab>, <source>FastStats Arthritis</source>, (<year>2020</year>). <comment><ext-link xlink:href="https://www.cdc.gov/nchs/fastats/arthritis.htm" ext-link-type="uri">https://www.cdc.gov/nchs/fastats/arthritis.htm</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>January 25, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R50">
                <label>[50]</label>
                <mixed-citation publication-type="journal"><name><surname>Ayina</surname><given-names>Endomba</given-names></name>, <name><surname>Mandengue</surname><given-names>Noubiap</given-names></name>, <name><surname>Ngoa</surname><given-names>Boudou</given-names></name>, <name><surname>Gautier</surname><given-names>Mbanya</given-names></name>, <article-title>Sobngwi, association of the leptin-to-adiponectin ratio with metabolic syndrome in a sub-saharan african population</article-title>, <source>Diabetol. Metab. Syndr</source><volume>9</volume> (<year>2017</year>) <fpage>66</fpage>, <pub-id pub-id-type="doi">10.1186/s13098-017-0265-6</pub-id>.<pub-id pub-id-type="pmid">28878827</pub-id></mixed-citation>
              </ref>
              <ref id="R51">
                <label>[51]</label>
                <mixed-citation publication-type="journal"><name><surname>Nixon</surname></name>, <article-title>The inverse relationship between cancer and alzheimer’s disease: a possible mechanism</article-title>, <source>Curr. Alzhei. Res</source><volume>14</volume> (<year>2017</year>) <fpage>883</fpage>–<lpage>893</lpage>, <pub-id pub-id-type="doi">10.2174/1567205014666170216152905</pub-id>.</mixed-citation>
              </ref>
              <ref id="R52">
                <label>[52]</label>
                <mixed-citation publication-type="journal"><name><surname>Chou</surname><given-names>Hsu</given-names></name>, <name><surname>Wu</surname><given-names>Teng</given-names></name>, <name><surname>Sun</surname><given-names>Ko</given-names></name>, <article-title>Leptin-to-adiponectin ratio is related to low grade inflammation and insulin resistance independent of obesity in non-diabetic taiwanese: a cross-sectional cohort study</article-title>, <source>Acta. Cardiol. Sin</source><volume>30</volume> (<year>2014</year>) <fpage>204</fpage>–<lpage>214</lpage>.<pub-id pub-id-type="pmid">27122790</pub-id></mixed-citation>
              </ref>
              <ref id="R53">
                <label>[53]</label>
                <mixed-citation publication-type="journal"><name><surname>Fruhbeck</surname><given-names>Catalán</given-names></name>, <name><surname>Rodríguez</surname><given-names>Ramírez</given-names></name>, <name><surname>Becerril</surname><given-names>Salvador</given-names></name>, <name><surname>Portincasa</surname><given-names>Colina</given-names></name>, <article-title>Gómez-Ambrosi, Involvement of the leptin-adiponectin axis in inflammation and oxidative stress in the metabolic syndrome</article-title>, <source>Sci. Rep</source><volume>7</volume> (<year>2017</year>) <fpage>6619</fpage>, <pub-id pub-id-type="doi">10.1038/s41598-017-06997-0</pub-id>.<pub-id pub-id-type="pmid">28747790</pub-id></mixed-citation>
              </ref>
              <ref id="R54">
                <label>[54]</label>
                <mixed-citation publication-type="journal"><name><surname>Jialal</surname><given-names>Adams-Huet</given-names></name>, <name><surname>Duong</surname><given-names>Smith</given-names></name>, <article-title>Relationship between retinol-binding protein-4/adiponectin and leptin/adiponectin ratios with insulin resistance and inflammation</article-title>, <source>Metab. Syndr. Relat. Disord</source><volume>12</volume> (<year>2014</year>) <fpage>227</fpage>–<lpage>230</lpage>, <pub-id pub-id-type="doi">10.1089/met.2014.0013</pub-id>.<pub-id pub-id-type="pmid">24593134</pub-id></mixed-citation>
              </ref>
              <ref id="R55">
                <label>[55]</label>
                <mixed-citation publication-type="journal"><name><surname>Liang</surname><given-names>Hur</given-names></name>, <name><surname>Kang</surname><given-names>Rhee</given-names></name>, <name><surname>Kim</surname><given-names>Lee</given-names></name>, <article-title>Effect of the anti-il-17 antibody on allergic inflammation in an obesity-related asthma model</article-title>, <source>Kore. J. Intern. Med</source><volume>33</volume> (<year>2018</year>) <fpage>1210</fpage>–<lpage>1223</lpage>, <pub-id pub-id-type="doi">10.3904/kjim.2017.207</pub-id>.</mixed-citation>
              </ref>
              <ref id="R56">
                <label>[56]</label>
                <mixed-citation publication-type="journal"><name><surname>Panahi</surname><given-names>Khalili</given-names></name>, <name><surname>Sahebi</surname><given-names>Namazi</given-names></name>, <name><surname>Atkin</surname><given-names>Majeed</given-names></name>, <article-title>Sahebkar, Curcuminoids plus piperine modulate adipokines in type 2 diabetes mellitus</article-title>, <source>Curr. Clin. Pharmacol</source><volume>12</volume> (<year>2017</year>) <fpage>253</fpage>–<lpage>258</lpage>, <pub-id pub-id-type="doi">10.2174/1574884713666180104095641</pub-id>.<pub-id pub-id-type="pmid">29299989</pub-id></mixed-citation>
              </ref>
              <ref id="R57">
                <label>[57]</label>
                <mixed-citation publication-type="journal"><name><surname>Jacobo-Cejudo</surname><given-names>Valdés-Ramos</given-names></name>, <name><surname>Guadarrama-López</surname><given-names>Pardo-Morales</given-names></name>, <article-title>Harbige Martínez-Carrillo, Effect of n-3 polyunsaturated fatty acid supplementation on metabolic and inflammatory biomarkers in type 2 diabetes mellitus patients</article-title>, <source>Nutrie</source><volume>9</volume> (<year>2017</year>), <pub-id pub-id-type="doi">10.3390/nu9060573</pub-id>.</mixed-citation>
              </ref>
              <ref id="R58">
                <label>[58]</label>
                <mixed-citation publication-type="journal"><name><surname>Vargas</surname><given-names>Almario</given-names></name>, <name><surname>Buchan</surname><given-names>Kim</given-names></name>, <article-title>Karakas, metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome</article-title>, <source>Metab.-Clin. Exp</source><volume>60</volume> (<year>2011</year>) <fpage>1711</fpage>–<lpage>1718</lpage>, <pub-id pub-id-type="doi">10.1016/j.metabol.2011.04.007</pub-id>.<pub-id pub-id-type="pmid">21640360</pub-id></mixed-citation>
              </ref>
              <ref id="R59">
                <label>[59]</label>
                <mixed-citation publication-type="journal"><name><surname>Yamamoto</surname><given-names>Kajikawa</given-names></name>, <name><surname>Otani</surname><given-names>Yamada</given-names></name>, <name><surname>Takemoto</surname><given-names>Hirota</given-names></name>, <name><surname>Ikeda</surname><given-names>Iwagaki</given-names></name>, <name><surname>Saito</surname><given-names>Fujiwara</given-names></name>, <article-title>Protective effect of eicosapentaenoic acid on insulin resistance in hyperlipidemic patients and on the postoperative course of cardiac surgery patients: the possible involvement of adiponectin</article-title>, <source>Acta Med. Okayama</source><volume>68</volume> (<year>2014</year>) <fpage>349</fpage>–<lpage>361</lpage>, <pub-id pub-id-type="doi">10.18926/AMO/53024</pub-id>.<pub-id pub-id-type="pmid">25519029</pub-id></mixed-citation>
              </ref>
              <ref id="R60">
                <label>[60]</label>
                <mixed-citation publication-type="journal"><name><surname>Krebs</surname><given-names>Browning</given-names></name>, <name><surname>McLean</surname><given-names>Rothwell</given-names></name>, <name><surname>Mishra</surname><given-names>Moore</given-names></name>, <article-title>Jebb, additive benefits of long-chain n-3 polyunsaturated fatty acids and weight-loss in the management of cardiovascular disease risk in overweight hyperinsulinaemic women</article-title>, <source>Int. J Obes. (Lond)</source><volume>30</volume> (<year>2006</year>) <fpage>1535</fpage>–<lpage>1544</lpage>, <pub-id pub-id-type="doi">10.1038/sj.ijo.0803309</pub-id>.<pub-id pub-id-type="pmid">16552404</pub-id></mixed-citation>
              </ref>
              <ref id="R61">
                <label>[61]</label>
                <mixed-citation publication-type="journal"><name><surname>Qin</surname><given-names>Zhou</given-names></name>, <name><surname>Chen</surname><given-names>Zhao</given-names></name>, <name><surname>Ran</surname><given-names>Zeng</given-names></name>, <name><surname>Wu</surname><given-names>Chen</given-names></name>, <name><surname>Kang</surname><given-names>Shu</given-names></name>, <name><surname>Zhang</surname><given-names>Mi</given-names></name>, <article-title>Fish oil supplements lower serum lipids and glucose in correlation with a reduction in plasma fibroblast growth factor 21 and prostaglandin e2 in nonalcoholic fatty liver disease associated with hyperlipidemia: a randomized clinical trial</article-title>, <source>PLoS ONE</source><volume>10</volume> (<year>2015</year>), <fpage>e0133496</fpage>, <pub-id pub-id-type="doi">10.1371/journal.pone.0133496</pub-id>.<pub-id pub-id-type="pmid">26226139</pub-id></mixed-citation>
              </ref>
              <ref id="R62">
                <label>[62]</label>
                <mixed-citation publication-type="journal"><name><surname>Everson-Rose</surname><given-names>Clark</given-names></name>, <name><surname>Wang</surname><given-names>Guo</given-names></name>, <name><surname>Mancuso</surname><given-names>Kravitz</given-names></name>, <article-title>Bromberger, depressive symptoms and adipokines in women: study of women’s health across the nation</article-title>, <source>Psychoneuroendocrinol</source><volume>97</volume> (<year>2018</year>) <fpage>20</fpage>–<lpage>27</lpage>, <pub-id pub-id-type="doi">10.1016/j.psyneuen.2018.07.011</pub-id>.</mixed-citation>
              </ref>
              <ref id="R63">
                <label>[63]</label>
                <mixed-citation publication-type="journal"><name><surname>Katsiki</surname><given-names>Mikhailidis</given-names></name>, <article-title>Banach, leptin, cardiovascular diseases and type 2 diabetes mellitus</article-title>, <source>Acta. Pharmacol. Sin</source><volume>39</volume> (<year>2018</year>) <fpage>1176</fpage>–<lpage>1188</lpage>, <pub-id pub-id-type="doi">10.1038/aps.2018.40</pub-id>.<pub-id pub-id-type="pmid">29877321</pub-id></mixed-citation>
              </ref>
              <ref id="R64">
                <label>[64]</label>
                <mixed-citation publication-type="journal"><name><surname>Su</surname><given-names>Lu</given-names></name>, <name><surname>Su</surname><given-names>Zhao</given-names></name>, <name><surname>Dong</surname><given-names>Sun</given-names></name>, <name><surname>Zhao</surname><given-names>Li</given-names></name>, <article-title>Relationship of serum adiponectin levels and metformin therapy in patients with type 2 diabetes</article-title>, <source>Horm. Metab. Res</source><volume>48</volume> (<year>2016</year>) <fpage>92</fpage>–<lpage>98</lpage>, <pub-id pub-id-type="doi">10.1055/s-0035-1569287</pub-id>.<pub-id pub-id-type="pmid">26808583</pub-id></mixed-citation>
              </ref>
              <ref id="R65">
                <label>[65]</label>
                <mixed-citation publication-type="journal"><name><surname>Malin</surname><given-names>Kashyap</given-names></name>, <article-title>Effects of metformin on weight loss: potential mechanisms</article-title>, <source>Curr Opin Endocrinol Diab. Obes</source><volume>21</volume> (<year>2014</year>) <fpage>323</fpage>–<lpage>329</lpage>, <pub-id pub-id-type="doi">10.1097/MED.0000000000000095</pub-id>.</mixed-citation>
              </ref>
              <ref id="R66">
                <label>[66]</label>
                <mixed-citation publication-type="journal"><name><surname>Katsiki</surname><given-names>Mikhailidis</given-names></name>, <name><surname>Gotzamani-Psarrakou</surname><given-names>Yovos</given-names></name>, <article-title>Karamitsos, effect of various treatments on leptin, adiponectin, ghrelin and neuropeptide y in patients with type 2 diabetes mellitus</article-title>, <source>Expe. Opin. Ther. Targ</source><volume>15</volume> (<year>2011</year>) <fpage>401</fpage>–<lpage>420</lpage>, <pub-id pub-id-type="doi">10.1517/14728222.2011.553609</pub-id>.</mixed-citation>
              </ref>
              <ref id="R67">
                <label>[67]</label>
                <mixed-citation publication-type="journal"><name><surname>Schooling</surname><given-names>Luo</given-names></name>, <name><surname>Yeung</surname><given-names>Au</given-names></name>, <name><surname>Thompson</surname><given-names>Karthikeyan</given-names></name>, <name><surname>Bolton</surname><given-names>Mason</given-names></name>, <name><surname>Ingelsson</surname><given-names>Burgess</given-names></name>, <article-title>Genetic predictors of testosterone and their associations with cardiovascular disease and risk factors: a mendelian randomization investigation</article-title>, <source>Int. J. Cardiol</source><volume>267</volume> (<year>2018</year>) <fpage>171</fpage>–<lpage>176</lpage>, <pub-id pub-id-type="doi">10.1016/j.ijcard.2018.05.051</pub-id>.<pub-id pub-id-type="pmid">29804699</pub-id></mixed-citation>
              </ref>
              <ref id="R68">
                <label>[68]</label>
                <mixed-citation publication-type="journal"><name><surname>Tilija Pun</surname><given-names>N</given-names></name>, <name><surname>Park</surname><given-names>P–H</given-names></name>, <article-title>Adiponectin inhibits inflammatory cytokines production by beclin-1 phosphorylation and b-cell lymphoma 2 mrna destabilization: role for autophagy induction</article-title>, <source>Br. J. Pharmacol</source><volume>175</volume> (<year>2018</year>) <fpage>1066</fpage>–<lpage>1084</lpage>, <pub-id pub-id-type="doi">10.1111/bph.14144</pub-id>.<pub-id pub-id-type="pmid">29333604</pub-id></mixed-citation>
              </ref>
              <ref id="R69">
                <label>[69]</label>
                <mixed-citation publication-type="journal"><name><surname>Elfeky</surname><given-names>M</given-names></name>, <name><surname>Yoneshiro</surname><given-names>T</given-names></name>, <name><surname>Okamatsu-Ogura</surname><given-names>Y</given-names></name>, <name><surname>Kimura</surname><given-names>K</given-names></name>, <article-title>Adiponectin suppression of late inflammatory mediator, hmgb1-induced cytokine expression in raw264 macrophage cells</article-title>, <source>J. Biochem</source><volume>163</volume> (<year>2018</year>) <fpage>143</fpage>–<lpage>153</lpage>, <pub-id pub-id-type="doi">10.1093/jb/mvx069</pub-id>.<pub-id pub-id-type="pmid">29048484</pub-id></mixed-citation>
              </ref>
              <ref id="R70">
                <label>[70]</label>
                <mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>Feng</given-names></name>, <name><surname>Li</surname><given-names>Wang</given-names></name>, <name><surname>Li</surname><given-names>Hua</given-names></name>, <article-title>Adiponectin, tnf-α and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis</article-title>, <source>Cytok</source><volume>86</volume> (<year>2016</year>) <fpage>100</fpage>–<lpage>109</lpage>, <pub-id pub-id-type="doi">10.1016/j.cyto.2016.06.028</pub-id>.</mixed-citation>
              </ref>
              <ref id="R71">
                <label>[71]</label>
                <mixed-citation publication-type="journal"><name><surname>Lopez-Jaramillo</surname><given-names>Gómez-Arbeláez</given-names></name>, <name><surname>López-López</surname><given-names>López-López</given-names></name>, <name><surname>Martínez-Ortega</surname><given-names>Gómez-Rodríguez</given-names></name>, <name><surname>Triana-Cubillos</surname></name>, <article-title>The role of leptin/adiponectin ratio in metabolic syndrome and diabetes</article-title>, <source>Horm. Mol. Biol. Clin. Investig</source><volume>18</volume> (<year>2014</year>) <fpage>37</fpage>–<lpage>45</lpage>, <pub-id pub-id-type="doi">10.1515/hmbci-2013-0053</pub-id>.</mixed-citation>
              </ref>
              <ref id="R72">
                <label>[72]</label>
                <mixed-citation publication-type="journal"><name><surname>Rapaport</surname><given-names>Nierenberg</given-names></name>, <name><surname>Schettler</surname><given-names>Kinkead</given-names></name>, <name><surname>Cardoos</surname><given-names>Walker</given-names></name>, <article-title>Mischoulon, inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study</article-title>, <source>Mol. Psychia</source><volume>21</volume> (<year>2016</year>) <fpage>71</fpage>–<lpage>79</lpage>, <pub-id pub-id-type="doi">10.1038/mp.2015.22</pub-id>.</mixed-citation>
              </ref>
              <ref id="R73">
                <label>[73]</label>
                <mixed-citation publication-type="journal"><name><surname>Borges</surname><given-names>Franca</given-names></name>, <name><surname>Fujimori</surname><given-names>Silva</given-names></name>, <article-title>Deluque de Marchi, de Abreu Honorio-Franca, Relationship between proinflammatory cytokines/chemokines and adipokines in serum of young adults with obesity</article-title>, <source>Endocr. Metab. Immu. Disord. Drug Targ</source><volume>18</volume> (<year>2018</year>) <fpage>260</fpage>–<lpage>267</lpage>, <pub-id pub-id-type="doi">10.2174/1871530318666180131094733</pub-id>.</mixed-citation>
              </ref>
              <ref id="R74">
                <label>[74]</label>
                <mixed-citation publication-type="journal"><name><surname>Leaf</surname><given-names>Jorgensen</given-names></name>, <name><surname>Jacobs</surname><given-names>Cote</given-names></name>, <name><surname>Scheer Schoenfeld</surname><given-names>J</given-names></name>, <name><surname>Weiner</surname><given-names>Slack</given-names></name>, <name><surname>Kellett</surname><given-names>Raizner</given-names></name>, <article-title>Do fish oils prevent restenosis after coronary angioplasty?</article-title><source>Circul</source><volume>90</volume> (<year>1994</year>) <fpage>2248</fpage>–<lpage>2257</lpage>, <pub-id pub-id-type="doi">10.1161/01.cir.90.5.2248</pub-id>.</mixed-citation>
              </ref>
              <ref id="R75">
                <label>[75]</label>
                <mixed-citation publication-type="other"><collab>U.S. Food and Drug Administration Center for Food Safety and Applied Nutrition Office of Nutritional Products Labeling and Dietary Supplements (FDA/CSFAN)</collab>., <source>Letter Regarding Dietary Supplement Health Claim For omega-3 Fatty Acids and Coronary Heart disease. (Docket No. 91N-0103)</source>, (<year>2000</year>).</mixed-citation>
              </ref>
              <ref id="R76">
                <label>[76]</label>
                <mixed-citation publication-type="journal"><name><surname>Krantz</surname><given-names>Havranek</given-names></name>, <name><surname>Pereira</surname><given-names>Beaty</given-names></name>, <name><surname>Mehler</surname><given-names>Long</given-names></name>, <article-title>Effects of omega-3 fatty acids on arterial stiffness in patients with hypertension: a randomized pilot study</article-title>, <source>J. Negat. Resul.Biomed</source><volume>14</volume> (<year>2015</year>) <fpage>21</fpage>, <pub-id pub-id-type="doi">10.1186/s12952-015-0040-x</pub-id>.</mixed-citation>
              </ref>
              <ref id="R77">
                <label>[77]</label>
                <mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>Ivester</given-names></name>, <name><surname>Hester</surname><given-names>Sergeant</given-names></name>, <name><surname>Case</surname><given-names>Morgan</given-names></name>, <name><surname>Kouba</surname><given-names>Chilton</given-names></name>, <article-title>The impact of polyunsaturated fatty acid-based dietary supplements on disease biomarkers in a metabolic syndrome/diabetes population</article-title>, <source>Lip. Heal. Dis</source> (<year>2014</year>). <pub-id pub-id-type="doi">10.1186/1476-511X-13-196</pub-id>.</mixed-citation>
              </ref>
              <ref id="R78">
                <label>[78]</label>
                <mixed-citation publication-type="journal"><name><surname>Simao</surname><given-names>Lozovoy</given-names></name>, <name><surname>Bahls</surname><given-names>Morimoto</given-names></name>, <name><surname>Matsuo</surname></name>, <name><surname>Simão</surname><given-names>Dichi</given-names></name>, <article-title>Blood pressure decrease with ingestion of a soya product (kinako) or fish oil in women with the metabolic syndrome: role of adiponectin and nitric oxide</article-title>, <source>Br. J. Nutr</source><volume>108</volume> (<year>2012</year>) <fpage>1435</fpage>–<lpage>1442</lpage>, <pub-id pub-id-type="doi">10.1017/S0007114511006921</pub-id>.<pub-id pub-id-type="pmid">22313793</pub-id></mixed-citation>
              </ref>
              <ref id="R79">
                <label>[79]</label>
                <mixed-citation publication-type="journal"><name><surname>Spencer</surname><given-names>Finlin</given-names></name>, <name><surname>Unal</surname><given-names>Zhu</given-names></name>, <name><surname>Morris</surname><given-names>Shipp</given-names></name>, <name><surname>Lee</surname><given-names>Walton</given-names></name>, <name><surname>Adu</surname><given-names>Erfani</given-names></name>, <name><surname>Campbell</surname><given-names>McGehee</given-names></name>, <name><surname>Peterson</surname><given-names>Kern</given-names></name>, <article-title>Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance</article-title>, <source>Diab</source><volume>62</volume> (<year>2013</year>) <fpage>1709</fpage>–<lpage>1717</lpage>, <pub-id pub-id-type="doi">10.2337/db12-1042</pub-id>.</mixed-citation>
              </ref>
              <ref id="R80">
                <label>[80]</label>
                <mixed-citation publication-type="journal"><name><surname>Troseid</surname><given-names>Arnesen</given-names></name>, <name><surname>Hjerkinn</surname><given-names>Seljeflot</given-names></name>, <article-title>Serum levels of interleukin-18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men</article-title>, <source>Metab. Clin. Exp</source><volume>58</volume> (<year>2009</year>) <fpage>1543</fpage>–<lpage>1549</lpage>, <pub-id pub-id-type="doi">10.1016/j.metabol.2009.04.031</pub-id>.<pub-id pub-id-type="pmid">19595382</pub-id></mixed-citation>
              </ref>
              <ref id="R81">
                <label>[81]</label>
                <mixed-citation publication-type="journal"><name><surname>Allaire</surname><given-names>Couture</given-names></name>, <name><surname>Leclerc</surname><given-names>Charest</given-names></name>, <name><surname>Lépine Marin</surname><given-names>M-C</given-names></name>, <name><surname>Talbot</surname><given-names>D</given-names></name>, <name><surname>Tchernof</surname><given-names>A</given-names></name>, <name><surname>Lamarche</surname><given-names>B</given-names></name>, <article-title>A randomized, crossover, head-to-head comparison of eicosapentaenoic acid and docosahexaenoic acid supplementation to reduce inflammation markers in men and women: the comparing epa to dha (compared) study</article-title>, <source>Am. J. Clin. Nutr</source><volume>104</volume> (<year>2016</year>) <fpage>280</fpage>–<lpage>287</lpage>, <pub-id pub-id-type="doi">10.3945/ajcn.116.131896</pub-id>.<pub-id pub-id-type="pmid">27281302</pub-id></mixed-citation>
              </ref>
              <ref id="R82">
                <label>[82]</label>
                <mixed-citation publication-type="journal"><name><surname>Haidari</surname><given-names>Tavakoli</given-names></name>, <name><surname>Heybar</surname><given-names>Helli</given-names></name>, <article-title>Mohammadshahi, The effect of omega-3 on the level of serum lipid profile, adipocytokines, and indicator of vascular inflammation in patients diagnosed with myocardial infarction</article-title>, <source>J. Babol Uni. Medi. Sci</source><volume>17</volume> (<year>2015</year>) <fpage>7</fpage>–<lpage>17</lpage>.</mixed-citation>
              </ref>
              <ref id="R83">
                <label>[83]</label>
                <mixed-citation publication-type="journal"><name><surname>Satoh</surname><given-names>Shimatsu</given-names></name>, <name><surname>Kotani</surname><given-names>Himeno</given-names></name>, <name><surname>Majima</surname><given-names>Yamada</given-names></name>, <name><surname>Suganami</surname><given-names>Ogawa</given-names></name>, <article-title>Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid a-ldl in metabolic syndrome</article-title>, <source>Hypertens. Res</source><volume>32</volume> (<year>2009</year>) <fpage>1004</fpage>–<lpage>1008</lpage>, <pub-id pub-id-type="doi">10.1038/hr.2009.145</pub-id>.<pub-id pub-id-type="pmid">19763135</pub-id></mixed-citation>
              </ref>
              <ref id="R84">
                <label>[84]</label>
                <mixed-citation publication-type="journal"><name><surname>Satoh-Asahara</surname><given-names>Shimatsu</given-names></name>, <name><surname>Sasaki</surname><given-names>Nakaoka</given-names></name>, <name><surname>Himeno</surname><given-names>Tochiya</given-names></name>, <name><surname>Kono</surname><given-names>Takaya</given-names></name>, <name><surname>Ono</surname><given-names>Wada</given-names></name>, <name><surname>Suganami</surname><given-names>Hasegawa</given-names></name>, <article-title>Ogawa, highly purified eicosapentaenoic acid increases interleukin-10 levels of peripheral blood monocytes in obese patients with dyslipidemia</article-title>, <source>Diab. Care</source><volume>35</volume> (<year>2012</year>) <fpage>2631</fpage>–<lpage>2639</lpage>, <pub-id pub-id-type="doi">10.2337/dc12-0269</pub-id>.</mixed-citation>
              </ref>
              <ref id="R85">
                <label>[85]</label>
                <mixed-citation publication-type="journal"><name><surname>Villani</surname><given-names>Crotty</given-names></name>, <name><surname>Cleland</surname><given-names>James</given-names></name>, <name><surname>Fraser</surname><given-names>Cobiac</given-names></name>, <article-title>Miller, fish oil administration in older adults with cardiovascular disease or cardiovascular risk factors: is there potential for adverse events? a systematic review of the literature</article-title>, <source>Int. J. Cardiol</source><volume>168</volume> (<year>2013</year>) <fpage>4371</fpage>–<lpage>4375</lpage>, <pub-id pub-id-type="doi">10.1016/j.ijcard.2013.05.054</pub-id>.<pub-id pub-id-type="pmid">23742929</pub-id></mixed-citation>
              </ref>
              <ref id="R86">
                <label>[86]</label>
                <mixed-citation publication-type="journal"><name><surname>Olshansky</surname><given-names>B</given-names></name>, <name><surname>Chung</surname><given-names>MK</given-names></name>, <name><surname>Budoff</surname><given-names>MJ</given-names></name>, <name><surname>Philip</surname><given-names>S</given-names></name>, <name><surname>Jiao</surname><given-names>L</given-names></name>, <name><surname>Doyle</surname><given-names>RT</given-names><suffix>Jr.</suffix></name>, <name><surname>Copland</surname><given-names>C</given-names></name>, <name><surname>Giaquinto</surname><given-names>A</given-names></name>, <name><surname>Juliano</surname><given-names>RA</given-names></name>, <name><surname>Bhatt</surname><given-names>DL</given-names></name>, <article-title>Mineral oil: safety and use as placebo in reduce-it and other clinical studies</article-title>, <source>Euro. Hear. J. Suppl</source><volume>22</volume> (<year>2020</year>) <fpage>J34</fpage>–<lpage>J48</lpage>, <pub-id pub-id-type="doi">10.1093/eurheartj/suaa117</pub-id>.</mixed-citation>
              </ref>
              <ref id="R87">
                <label>[87]</label>
                <mixed-citation publication-type="journal"><name><surname>Sakamoto</surname><given-names>A</given-names></name>, <name><surname>Saotome</surname><given-names>M</given-names></name>, <name><surname>Iguchi</surname><given-names>K</given-names></name>, <name><surname>Maekawa</surname><given-names>Y</given-names></name>, <article-title>Marine-Derived omega-3 polyunsaturated fatty acids and heart failure: current understanding for basic to clinical relevance</article-title>, <source>Int J Mol Sci</source><volume>20</volume> (<year>2019</year>), <pub-id pub-id-type="doi">10.3390/ijms20164025</pub-id>.</mixed-citation>
              </ref>
              <ref id="R88">
                <label>[88]</label>
                <mixed-citation publication-type="journal"><name><surname>Rausch</surname><given-names>J</given-names></name>, <name><surname>Gillespie</surname><given-names>S</given-names></name>, <name><surname>Orchard</surname><given-names>T</given-names></name>, <name><surname>Tan</surname><given-names>A</given-names></name>, <name><surname>McDaniel</surname><given-names>JC</given-names></name>, <article-title>Systematic review of marine-derived omega-3 fatty acid supplementation effects on leptin, adiponectin, and the leptin-to-adiponectin ratio</article-title>, <source>Nutr. Res.</source> (<year>2020</year>).</mixed-citation>
              </ref>
              <ref id="R89">
                <label>[89]</label>
                <mixed-citation publication-type="webpage"><collab>Mayo Clinic Labs</collab>, <source>Leptin</source>. (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/91339" ext-link-type="uri">https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/91339</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 3, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R90">
                <label>[90]</label>
                <mixed-citation publication-type="webpage"><collab>Cleveland Clinic Laboratories Test Directory</collab>, <source>Leptin</source>. (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://ltd.clevelandcliniclabs.com/test/3201" ext-link-type="uri">https://ltd.clevelandcliniclabs.com/test/3201</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 4, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R91">
                <label>[91]</label>
                <mixed-citation publication-type="webpage"><collab>Johns Hopkins Hospital</collab>, <source>Leptin</source> (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://pathology.jhu.edu/jhml-services/test-directory/" ext-link-type="uri">https://pathology.jhu.edu/jhml-services/test-directory/</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 3, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R92">
                <label>[92]</label>
                <mixed-citation publication-type="webpage"><collab>Quest Diagnostics</collab>, <source>Leptin</source>. (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://testdirectory.questdiagnostics.com/test/test-detail/90367/leptin?cc=MASTER" ext-link-type="uri">https://testdirectory.questdiagnostics.com/test/test-detail/90367/leptin?cc=MASTER</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 3, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R93">
                <label>[93]</label>
                <mixed-citation publication-type="webpage"><collab>Mayo Clinic Labs</collab>, <source>Adiponectin</source>. (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/75607" ext-link-type="uri">https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/75607</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 3, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R94">
                <label>[94]</label>
                <mixed-citation publication-type="webpage"><collab>Cleveland Clinic Laboratories Test Directory</collab>, <source>Adiponectin</source>. (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://ltd.clevelandcliniclabs.com/test/4199" ext-link-type="uri">https://ltd.clevelandcliniclabs.com/test/4199</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 4, 2021</date-in-citation>).</mixed-citation>
              </ref>
              <ref id="R95">
                <label>[95]</label>
                <mixed-citation publication-type="webpage"><collab>Johns Hopkins Hospital</collab>, <source>Adiponectin</source>. (<comment>n.d.</comment>). <comment><ext-link xlink:href="https://pathology.jhu.edu/jhml-services/test-directory/" ext-link-type="uri">https://pathology.jhu.edu/jhml-services/test-directory/</ext-link></comment> (<comment>accessed</comment>
<date-in-citation>March 3, 2021</date-in-citation>).</mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="F1">
              <label>Fig. 1.</label>
              <caption>
                <p id="P66">Role of leptin and adiponectin in inflammation. Leptin and adiponectin are primarily secreted by adipocytes; after entry into peripheral circulation they act as hormones, helping to regulate inflammatory responses. The figure depicts the anti-inflammatory effects of adiponectin on the left and the proinflammatory effects of leptin on the right in lean individuals. In aging and obesity, an imbalance in leptin and adiponectin is hypothesized to amplify systemic inflammation.</p>
              </caption>
              <graphic xlink:href="nihms-1773009-f0001" position="float"/>
            </fig>
            <fig position="float" id="F2">
              <label>Fig. 2.</label>
              <caption>
                <p id="P67">Hypothesized effects of EPA+DHA on leptin and adiponectin. Although the exact mechanisms remain unclear, it has been suggested that supplementing diets with EPA+DHA decrease leptin levels and increase adiponectin levels through four main hypotheses: 1) Direct or indirect alteration in expression of the genes that encode for leptin and adiponectin (Lep and Adipoq, respectively) [<xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R12" ref-type="bibr">12</xref>, <xref rid="R30" ref-type="bibr">30</xref>–<xref rid="R32" ref-type="bibr">32</xref>]; 2) Reduction of adipocyte size [<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref>]; 3) Decrease in adiposity [<xref rid="R29" ref-type="bibr">29</xref>,<xref rid="R31" ref-type="bibr">31</xref>,<xref rid="R32" ref-type="bibr">32</xref>]; and, 4) Improvement of insulin sensitivity [<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R35" ref-type="bibr">35</xref>].</p>
              </caption>
              <graphic xlink:href="nihms-1773009-f0002" position="float"/>
            </fig>
            <fig position="float" id="F3">
              <label>Fig. 3.</label>
              <caption>
                <p id="P68">CONSORT diagram of participant flow through parent study and inclusion in secondary analysis. The CONSORT diagram depicts the flow of participants through the parent study from eligibility assessment through completion of the parent study and inclusion in secondary analysis. Of the 264 persons assessed for eligibility 40 participants met inclusion and exclusion criteria and were randomized into the two groups. Thirty-five of those 40 participants completed the entire parent study. Of the 35 participants that completed the parent study, only 32 had complete leptin and adiponectin data for all three study time points. As such, data from 32 participants were included in this secondary data analysis.</p>
              </caption>
              <graphic xlink:href="nihms-1773009-f0003" position="float"/>
            </fig>
            <fig position="float" id="F4">
              <label>Fig. 4.</label>
              <caption>
                <p id="P69">Plasma Levels of EPA+DHA by Treatment Groups at Study Time Points. At baseline, both groups had similar levels of plasma EPA+DHA (EPA+DHA group <italic toggle="yes">M</italic> = 2.02, SE = 0.18 and Control group <italic toggle="yes">M</italic> = 1.95, SE = 0.11, t(30) = 0.37, <italic toggle="yes">p</italic> = .71, <italic toggle="yes">d</italic> = 0.12). The EPA+DHA group had significantly higher plasma levels of EPA+DHA at week 4 (<italic toggle="yes">M</italic> = 5.01, SE = 0.56) and at week 8 (<italic toggle="yes">M</italic> = 5.48, SE = 0.53) compared to week 0 (<italic toggle="yes">M</italic> = 2.02, SE = 0.18), t(13) = −5.12, <italic toggle="yes">p</italic> &lt; .001, <italic toggle="yes">t</italic> = −7.44, <italic toggle="yes">p</italic> &lt; .001, respectively. alternatively, the Control group did not show significant changes in plasma levels of EPA+DHA across time (week 0: <italic toggle="yes">M</italic> = 1.95, SE = 0.11; Week 4: <italic toggle="yes">M</italic> = 1.92, SE = 0.13; week 8: <italic toggle="yes">M</italic> = 1.92, SE = 0.14), t(17) = 0.438, <italic toggle="yes">p</italic> = .67, t(17) = 0.437, <italic toggle="yes">p</italic> = .67, respectively. The between-group analysis showed that the plasma levels of EPA+DHA were significantly higher in the EPA+DHA group at week 4 (<italic toggle="yes">M</italic> = 5.01, SE = 0.56) and at week 8 (<italic toggle="yes">M</italic> = 5.48, SE = 0.53) compared to the Control group (week 4: <italic toggle="yes">M</italic> = 1.92, SE = 0.13; week 8: <italic toggle="yes">M</italic> = 1.92, SE = 0.14), t(30) = 5.997, <italic toggle="yes">d</italic> = 2.01, <italic toggle="yes">p</italic> &lt; .001, t(30) = 7.218, <italic toggle="yes">p</italic> &lt; .001, <italic toggle="yes">d</italic> = 2.42, respectively. This indicates that both groups adhered to the study protocol and that the treatment dose was adequate to significantly change plasma levels of EPA+DHA. EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid. Error bars represent ±SEs. Between group analyses revealed significant differences at Week 4 and Week 8, <italic toggle="yes">p</italic> &lt; 0.001, &lt; 0.001, respectively.</p>
              </caption>
              <graphic xlink:href="nihms-1773009-f0004" position="float"/>
            </fig>
            <table-wrap position="float" id="T1">
              <label>Table 1</label>
              <caption>
                <p id="P70">Hypothesized Mechanisms of action of EPA+DHA on leptin and adiponectin.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="middle" rowspan="1" colspan="1">Mechanism</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">Leptin</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">Adiponectin</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">References</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Promote healthy weight</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↓</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↑</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R25" ref-type="bibr">25</xref>]</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Reduce adipocyte size</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↓</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↑</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R88" ref-type="bibr">88</xref>]</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Improve insulin sensitivity</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↓</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↑</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref>]</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Reduce <italic toggle="yes">Lep</italic> and increase <italic toggle="yes">Adipoq</italic> gene expression</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↓</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">↑</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">[<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R30" ref-type="bibr">30</xref>]</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN1">
                  <p id="P71">Lep and Adipoq are genes that encode for leptin and adiponectin, respectively. EPA = eicosapentaenoic acid, DHA = docosahexaenoic acid.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T2">
              <label>Table 2</label>
              <caption>
                <p id="P72">Fatty acids in study supplement as determined by independent analysis.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Fatty acid</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Common name</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Mg/capsule</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">% of total fatty acids</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C6:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Caproic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.10</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C8:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Caprylic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.0</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C14:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Myristic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.04</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.1</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C16:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Palmitic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">21.00</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.0</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C16:1</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Palmitoleic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7.94</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.8</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C18:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Stearic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">34.25</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3.4</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C18:1</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Oleic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">98.17</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9.7</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C18:2n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Linoleic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">30.09</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3.0</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C18:3n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Gamma-linolenic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.45</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.2</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C18:3n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Alpha-linolenic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7.27</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.7</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C18:4n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Stearidonic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">20.46</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.1</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Arachidic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9.99</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.0</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:1</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Eicosenoic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">36.80</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3.7</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:2n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Eicosadienoic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.99</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:3n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Dihomo-gamma-linolenic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.48</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:4n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Arachidonic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">20.32</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.1</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:3n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Eicosatrienoic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.70</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:4n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Eicosatetraenoic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">17.41</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.8</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C20:5n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Eicosapentaenoic Acid (EPA)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">324.67</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">33.4</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C21:5n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Heneicosapentaenoic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">16.59</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.51</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C22:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Behenic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4.43</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.5</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C22:1</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Cetoleic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">55.86</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.7</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C22:2n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Docosadienoic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.32</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.1</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C22:4n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Adrenic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3.56</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.4</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C22:5n6</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Docosapentaenoic Acid (n-6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">6.83</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.6</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C22:5n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Docosapentaenoic Acid (n-3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">47.05</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4.4</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C22:6n3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Docosahexaenoic Acid (DHA)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">217.78</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">21.2</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C24:0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Lignoceric Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.73</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.1</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">C24:1</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">Nervonic Acid</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.45</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.6</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Total fatty acids 998.81 100.0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                </tbody>
              </table>
            </table-wrap>
            <table-wrap position="float" id="T3">
              <label>Table 3</label>
              <caption>
                <p id="P73">Baseline characteristics of participants included in secondary analyses.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Factors</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Total Sample</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">EPA+DHA Group</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Control Group</th>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="left" valign="top" rowspan="1" colspan="1">n/M (%/SE)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">n/M (%/SE)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">n/M (%/SE)</th>
                    <th align="left" valign="top" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-value<xref rid="TFN3" ref-type="table-fn">*</xref></th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Participants</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">32 (100)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">14 (43.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">18 (56.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.48</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Age in Years</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">61.3 ± 2.1</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">60.8 ± 3.5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">61.6 ± 2.8</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.85</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Race</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.96</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">White</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">23 (71.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (71.4)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">11 (72.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">African American</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (28.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Sex</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.85</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Male</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">20 (62.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (64.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">11 (61.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Female</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">12 (37.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5 (35.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (38.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Marital Status</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.00</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Married/Living w/Someone</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">16 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Widow/Divorced/Single</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">16 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Education</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.58</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Some High School</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1 (3.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1 (5.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">High School Graduate</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">10 (31.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5 (35.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Some College</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">12 (37.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">8 (44.4)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">College Graduate or &gt;</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (28.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5 (35.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (22.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Employment Status</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.43</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Disabled/Unemployed</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">28 (87.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">13 (92.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">15 (83.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Employed Part-time</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2 (6.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0 (0)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2 (11.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Employed Full-time</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2 (6.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1 (7.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1 (5.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Annual Income</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.83</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt; $10,000</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (21.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3 (16.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">$10,000 – $24,999</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">11 (34.4)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (38.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">$25,000 – $44,999</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (12.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2 (14.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2 (11.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt; $45,000</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">10 (31.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">6 (33.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Smoking History</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.20</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Current Smoker</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">6 (18.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 (28.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2 (11.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Former Smoker</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">14 (43.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (38.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Never Smoker</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">12 (37.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3 (21.4)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (50)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.64</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">BMI</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">41.5 (2.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">40.4 (2.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">42.4 (3.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Comorbidities</td>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">CVD</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">25 (78.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">11 (78.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">14 (77.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.96</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Diabetes</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">16 (50.0)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">9 (64.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (38.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.29</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Arthritis</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">15 (46.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">8 (57.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7 (38.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.31</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">Depression</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">8 (25)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3 (21.4)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5 (27.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.68</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN2">
                  <p id="P74">EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; <italic toggle="yes">M</italic> = mean; SE = standard error; BMI = body mass index; CVD = cardiovascular disease; Meds = medications; L/<italic toggle="yes">A</italic> = leptin and/or adiponectin.</p>
                </fn>
                <fn id="TFN3">
                  <label>*</label>
                  <p id="P75">p-value represents the between group comparison.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T4">
              <label>Table 4</label>
              <caption>
                <p id="P76">Plasma leptin, adiponectin, and LAR data at Weeks 0, 4, and 8 by treatment group.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Transformed Measure</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Week</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">EPA+DHA Group</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Control Group</th>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                  </tr>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="left" valign="top" rowspan="1" colspan="1"/>
                    <th align="left" valign="top" rowspan="1" colspan="1">
                      <italic toggle="yes">Mean (SE)</italic>
                    </th>
                    <th align="left" valign="top" rowspan="1" colspan="1">
                      <italic toggle="yes">Mean (SE)</italic>
                    </th>
                    <th align="left" valign="top" rowspan="1" colspan="1">
                      <italic toggle="yes">p-value</italic>
                    </th>
                    <th align="left" valign="top" rowspan="1" colspan="1">
                      <italic toggle="yes">ES</italic>
                    </th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="6" align="left" valign="top" rowspan="1">Leptin</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">56.2 (14.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">79.1 (16.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.34</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.37</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">72.6 (10.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">83.4 (17.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.60</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.18</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">60.3 (13.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">77.2 (15.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.44</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.29</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 vs 0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">16.4 (11.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4.3 (8.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.38</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.32</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">8 vs 0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4.1 (5.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">−1.9 (7.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.55</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.23</td>
                  </tr>
                  <tr>
                    <td colspan="6" align="left" valign="top" rowspan="1">ADN</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">17.2 (8.7)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">27.2 (6.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.37</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.33</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">16.5 (8.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">29.2 (6.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.24</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.43</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">10.7 (8.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">32.9 (5.2)<xref rid="TFN5" ref-type="table-fn">*</xref><xref rid="TFN5" ref-type="table-fn">††</xref></td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.03</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.8</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 vs 0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">−0.7 (5.8)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2.1 (5.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.72</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.13</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">8 vs 0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">−6.5 (5.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.8 (4.9)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.11</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.60</td>
                  </tr>
                  <tr>
                    <td colspan="6" align="left" valign="top" rowspan="1">LAR</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">6.6 (1.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.5 (1.1)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.53</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.23</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">7.3 (1.2)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.9 (1.6)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.52</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.24</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.6 (1.5)<xref rid="TFN5" ref-type="table-fn">†</xref></td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.3 (1.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.86</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">4 vs 0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.6 (1.0)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.4 (0.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.56</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.21</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1"/>
                    <td align="left" valign="top" rowspan="1" colspan="1">8 vs 0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">−1.0 (1.3)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">−0.2 (0.5)</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.25</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN4">
                  <p id="P77">Original leptin and adiponectin data were not normally distributed. Data in this table has been transformed following a two-step process. Step-one transforms original data into a percentile rank, which results in a uniform distribution. Step-two applies an inverse-normal transformation to the result from step-one, resulting in a normally distributed dataset. The mean and standard deviation of the original variables are used during the transformation in to keep the same mean and standard deviation in the final resulting variable. Templeton (2011) details about the use of this process. EPA = eicosapentaenoic acid; DHA = docosahexaenoic acid; ES = effect size; SE = standard error; LAR = leptin-to-adiponectin ratio.</p>
                </fn>
                <fn id="TFN5">
                  <p id="P78">Between groups: * <italic toggle="yes">p</italic> = .03; Within groups: † EPA+DHA group from Week 4 to Week 8, <italic toggle="yes">p</italic> = .065; †† Control group from Week 4 to Week 8, <italic toggle="yes">p</italic> = .09.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T5">
              <label>Table 5</label>
              <caption>
                <p id="P79">Pearson Correlation coefficients (r) to determine relationships between leptin, adiponectin, leptin-to-adiponectin ratio (LAR) and cytokines.</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="middle" rowspan="1" colspan="1">Measure</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">W</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">1</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">2</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">3</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">4</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">5</th>
                    <th align="left" valign="middle" rowspan="1" colspan="1">6</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td colspan="8" align="left" valign="middle" rowspan="1">1. Leptin</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.08</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.81<xref rid="TFN8" ref-type="table-fn">**</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.10</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.40</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.08</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.05</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.7<xref rid="TFN8" ref-type="table-fn">**</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.11</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.05</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.08</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.19</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.25</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.03</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.28</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.27</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="left" valign="middle" rowspan="1">2. ADN</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.03</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.27</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.14</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.14</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.31</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.49<xref rid="TFN7" ref-type="table-fn">*</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.45</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.09</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.63<xref rid="TFN7" ref-type="table-fn">*</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.05</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.57<xref rid="TFN7" ref-type="table-fn">*</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.09</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.48</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.47</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.60<xref rid="TFN7" ref-type="table-fn">*</xref></td>
                  </tr>
                  <tr>
                    <td colspan="8" align="left" valign="middle" rowspan="1">3. LAR</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.84<xref rid="TFN7" ref-type="table-fn">*</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.52<xref rid="TFN7" ref-type="table-fn">*</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.14</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.46</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.06</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.93<xref rid="TFN8" ref-type="table-fn">**</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.68<xref rid="TFN8" ref-type="table-fn">**</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.05</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.12</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.31</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.94<xref rid="TFN8" ref-type="table-fn">**</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.73<xref rid="TFN8" ref-type="table-fn">**</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.19</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.04</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.42</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="left" valign="middle" rowspan="1">4. IL-6</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.13</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.19</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.03</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.32</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.1</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.30</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.25</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.23</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.02</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.37</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.32</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.20</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.30</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.01</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.15</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="left" valign="middle" rowspan="1">5. IL-1β</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.25</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.26</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.25</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.23</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.01</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.10</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.11</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.24</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.37</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.27</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.39</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.09</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.22</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.17</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.44</td>
                  </tr>
                  <tr>
                    <td colspan="8" align="left" valign="middle" rowspan="1">6. TNF-α</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.41</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.19</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.33</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.23</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.11</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.32</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.12</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.35</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.35</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.20</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                  </tr>
                  <tr>
                    <td align="left" valign="middle" rowspan="1" colspan="1"/>
                    <td align="left" valign="middle" rowspan="1" colspan="1">8</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.50<xref rid="TFN7" ref-type="table-fn">*</xref></td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.03</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.33</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">0.33</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">−0.01</td>
                    <td align="left" valign="middle" rowspan="1" colspan="1">–</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN6">
                  <p id="P80">The numbers 1–6 across the top row represent the same variables that are listed with the corresponding number in the first column. EPA+DHA Group correlations are shown ABOVE the diagonal dashes and the Control Group correlations are shown BELOW the dash line. <italic toggle="yes">W</italic> = week; ADN = adiponectin; LAR = leptin-to-adiponectin ratio; IL-6 = interleukin-6; IL-1β = interleukin-1 beta; TNF-α = tumor necrosis factor-alpha;</p>
                </fn>
                <fn id="TFN7">
                  <label>*</label>
                  <p id="P81"><italic toggle="yes">p</italic> &lt; .05,</p>
                </fn>
                <fn id="TFN8">
                  <label>**</label>
                  <p id="P82"><italic toggle="yes">p</italic> &lt; .01.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T6">
              <label>Table 6</label>
              <caption>
                <p id="P83">Leptin reference values (ng/ml).</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Source</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">BMI</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Sex</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Age</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Low Normal</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">High Normal</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td rowspan="2" align="left" valign="top" colspan="1">Mayo Clinic Labs [<xref rid="R89" ref-type="bibr">89</xref>]</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">22</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.7</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5.3</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">22</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">3.3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">18.3</td>
                  </tr>
                  <tr>
                    <td rowspan="2" align="left" valign="top" colspan="1">Cleveland Clinic Labs [<xref rid="R90" ref-type="bibr">90</xref>]</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">18 – 99</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">12.5</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">18 – 99</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">15.2</td>
                  </tr>
                  <tr>
                    <td rowspan="4" align="left" valign="top" colspan="1">Johns Hopkins Hospital Labs [<xref rid="R91" ref-type="bibr">91</xref>] &amp; Quest Diagnostics [<xref rid="R92" ref-type="bibr">92</xref>]</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">18 – 25</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">18 – 71</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">0.3</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">13.4</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">18 – 25</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">18 – 71</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4.7</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">23.7</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">25 – 30</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">19 – 60</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">1.8</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">19.9</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">25 – 30</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">19 – 60</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">8.0</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">38.9</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN9">
                  <p id="P84">BMI = body mass index; NS = not specified.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="T7">
              <label>Table 7</label>
              <caption>
                <p id="P85">Adiponectin reference values (mcg/ml).</p>
              </caption>
              <table frame="hsides" rules="groups">
                <colgroup span="1">
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                  <col align="left" valign="middle" span="1"/>
                </colgroup>
                <thead>
                  <tr>
                    <th align="left" valign="top" rowspan="1" colspan="1">Source</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">BMI</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Sex</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Age</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">Low Normal</th>
                    <th align="left" valign="top" rowspan="1" colspan="1">High Normal</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td rowspan="6" align="left" valign="top" colspan="1">Mayo Clinic Labs [<xref rid="R93" ref-type="bibr">93</xref>]; Cleveland Clinic Labs [<xref rid="R94" ref-type="bibr">94</xref>]; Johns Hopkins Hospital Labs [<xref rid="R95" ref-type="bibr">95</xref>]</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt; 25</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">26</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&lt; 25</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">37</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">25 – 30</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">20</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">25 – 30</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">28</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt; 30</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">M</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">20</td>
                  </tr>
                  <tr>
                    <td align="left" valign="top" rowspan="1" colspan="1">&gt; 30</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">F</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">NS</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                    <td align="left" valign="top" rowspan="1" colspan="1">22</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="TFN10">
                  <p id="P86">BMI = body mass index; NS = not specified.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
